e roche finance report roche finance report fhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom table contents roche group noncurrent liabilities finance brief debt finance brief equity attributable roche financial review shareholders roche group consolidated financial earnings per share statements nonvoting equity security notes roche group consolidated noncontrolling interests financial statements statement cash flows summary significant accounting risk management policies related parties operating segment information subsidiaries associates genentech report roche management chugai internal control financial reporting financial income financing costs report statutory auditor income taxes consolidated financial statements business combinations report independent auditor global restructuring plans internal control financial reporting employee benefits multiyear overview supplementary pensions postemployment information benefits roche securities employee stock options equity compensation plans property plant equipment roche holding ltd basel goodwill financial statements intangible assets notes financial statements associates summary significant accounting financial longterm assets policies inventories equity accounts receivable contingent liabilities current assets significant shareholders marketable securities risk management cash cash equivalents board executive remuneration accounts payable board executive shareholdings accrued current liabilities appropriation available earnings derivative financial instruments report statutory auditor provisions contingent liabilities financial statements roche finance report roche group finance brief finance brief key results local sales growth core operating profit margin sales pharmaceuticals diagnostics group change sales mchf mchf chf lc sales research development core operating profit operating profit operating free cash flow net income net income attributable roche shareholders free cash flow core eps chf diluted eps chf dividend per share chf december december change chf net cash debt capitalisation debt equity see pages definition core eps proposed board directors lc local currencies finance leadership team erich hunziker chief financial officer peter eisenring tax insurance christian hebich diagnostics finance andreas knierzinger treasury karl mahler investor relations patrick mongrolle pharma medicines finance erwin schneider controlling accounting nigel sheail business development petra storsberg pred finance finance brief roche finance report finance brief sales group sales billion swiss francs decline due large pandemic sales tamiflu comparative period currency translation effect strength swiss franc relative us dollar euro local currency sales stable growth underlying business compensated sharply reduced tamiflu sales excluding tamiflu group sales increased local currencies pharmaceuticals division sales grew market local currencies excluding tamiflu solid growth key oncology products lucentis ophthalmology actemraroactemra rheumatoid arthritis tamiflu sales declined sharply billion swiss francs billion swiss francs due pandemic hn influenza virus swine flu outbreak healthcare reforms united states austerity measures europe price cuts japan negative impact pharmaceuticals sales almost million swiss francs percentage points sales growth diagnostics sales increased local currencies billion swiss francs driven sales growth professional diagnostics diabetes care significantly ahead estimated ivd market growth rate operating results core operating profit increased local currencies billion swiss francs thanks genentech integration synergies productivity improvements offset substantially lower profit contribution tamiflu impact healthcare reforms core operating profit margin increased percentage points increase pharmaceuticals division percentage points diagnostics division percentage points research development expenditure core basis declined local currencies billion swiss francs representing group sales november group announced details operational excellence programme initial restructuring charges billion swiss francs included ifrs operating results mainly relating severance costs asset impairments treasury core net financial expenses increased million swiss francs primarily due full year financing costs debt issued first quarter respect genentech transaction losses early redemption debt repayment debt ahead schedule billion us dollars debt redeemed early september billion swiss francs bonds notes issued finance genentech transaction already repaid end billion us dollars called early redemption march financial condition strong financial condition operating free cash flow billion swiss francs free cash flow billion swiss francs net debt position billion swiss francs december billion billion swiss francs previous yearend strong credit rating moodys standard poors aa net income core eps net income increased billion swiss francs compared primarily driven strong operating result genentech transaction accretive impact net income attributable roche shareholders rose billion swiss francs synergies elimination noncontrolling interests compensated costs financing transaction core eps higher constant exchange rates higher swiss francs shareholder return increase proposed dividend swiss francs representing th consecutive year dividend growth approved shareholders result increased payout ratio higher dividend yield roche shares nonvoting equity securities based yearend prices decline total shareholder return tsr ie share price movement plus dividends combined performance share nonvoting equity security roche finance report roche group financial review roche group financial review group operating results sales billions chf core operating profit billions chf lc growth sales group achieved another solid operating performance sales stable local currencies swiss francs us dollars billion swiss francs underlying growth able compensate expected decline tamiflu sales initial impacts healthcare reforms austerity measures excluding tamiflu sales increased local currencies pharmaceuticals division represented group sales diagnostics division contributed sales pharmaceuticals division declined local currencies billion swiss francs excluding tamiflu local growth market growth demand oncology drugs avastin mabthera rituxan herceptin xeloda tarceva continued grow strongly additional major growth drivers lucentis ophthalmology actemraroactemra rheumatoid arthritis mircera renal anemia positive factors mostly offset expected decline tamiflu sales reduction cellcept sales due us patent expiry may impacts us healthcare reforms european austerity measures price cuts japan diagnostics division increased sales billion swiss francs growing local currencies swiss francs us dollars thereby strengthening leading market position major growth areas professional diagnostics diabetes care group expanded presentation core results previously core eps shown full income statement group operating results divisions shown ifrs core basis allows transparent assessment actual results underlying performance business core concept fully described pages reconciliations ifrs core results given core basis groups operating profit increased local currencies swiss francs sales stable increase profitability driven synergies genentech integration productivity improvements cost containment performance achieved spite substantially lower contribution tamiflu impacts healthcare reforms marketing distribution costs remained around prior years level local currencies research development costs declined pharmaceuticals division increased core operating profit local currencies driven primarily cost synergies genentech integration resource prioritisation productivity improvements core operating profit growth diagnostics division local currencies mainly resulting sales growth ongoing operational efficiency programmes groups core operating profit margin increased percentage points pharmaceuticals division improving percentage points diagnostics division percentage points margin increase group level lower two divisions due mix effect much stronger growth relatively lowermargin diagnostics business due shift certain administration activities pharmaceuticals division corporate result new group organisation effective january groups operating free cash flow remained strongly positive billion swiss francs decrease local currencies swiss francs principally arising payments early certain large yearend accrued liabilities notably tamiflu royalties employee retentionseverance schemes free cash flow decreased billion swiss francs billion swiss francs primarily due nonrecurrence onetime tax benefit billion swiss francs following genentech transaction interest payments new debt issued fund genentech transaction comparable payments higher dividend payments group continued pay debt issued first half finance genentech transaction november group announced details operational excellence programme consequence implementing respective restructuring measures significant costs incurred costs recognised billion swiss francs mainly relate severance payments following reductions positions sales marketing global manufacturing global development research early development well impairments intangible assets pharmaceuticals division accounts billion swiss francs costs billion swiss francs relate diagnostics division roughly charges noncash mostly impairments property plant equipment intangible assets pharmaceuticals division completed integration restructuring activities genentech expenses million swiss francs incurred mainly due site closure employeerelated costs comparative period million swiss francs incurred mainly impairment manufacturing facilities divisional operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales roche finance report roche group financial review divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase local currencies core operating profit increase local currencies margin percentage point increase operating profit increase local currencies margin percentage point increase operating free cash flow increase local currencies margin percentage point increase pharmaceuticals operating results sales pharmaceuticals division declined local currencies billion swiss francs excluding tamiflu local growth market growth core operating profit grew local currencies stable swiss francs billion swiss francs core operating profit margin increased percentage points driven genentech integration synergies resource prioritisation productivity improvements achieved spite expected sharp decline tamiflu sales billion swiss francs impact healthcare reforms austerity measures exchange rate movements negative percentage point effect margin marketing efforts focused growing oncology rheumatoid arthritis portfolios especially broader indications avastin herceptin launch actemraroactemra marketing distribution costs local currencies decreased tight cost management covered increase allowances bad debts southern europe research development costs reduced constant exchange rates whereas previous years increased significantly achieved resource prioritisation securing longterm growth rich pipeline pharmaceuticals division acquired us biopharmaceutical company marcadia biotech whose research programmes focus new peptide therapies treatment type diabetes obesity pharmaceuticals division incurred noncore expenses billion swiss francs relating operational excellence programme billion swiss francs relate termination costs shown global restructuring costs reconciliations core results remaining billion swiss francs consists impairments intangible assets also included global restructuring costs remaining costs billion swiss francs genentech integration restructuring pharmaceuticals division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales operating profit margin sales operating free cash flow margin sales sales sales therapeutic area major growth drivers key products oncology ophthalmology inflammationautoimmunetransplantation therapeutic areas virology sales tamiflu decreased substantially due unusually high sales arising hn influenza virus swine flu sales inflammationautoimmunetransplantation increased slightly due continued success mabthera rituxan rheumatoid arthritis well excellent uptake actemraroactemra compensated negative impact cellcept patent expiry united states may sales renal anemia therapeutic area decreased increasingly competitive costsensitive market pharmaceuticals division sales therapeutic area sales change therapeutic area mchf sales local currencies oncology virology inflammationautoimmunetransplantation metabolismbone ophthalmology renal anemia others total sales product top pharmaceuticals products represented sales pharmaceuticals portfolio declined local currencies growth contribution majority products could entirely offset expected significant decline tamiflu sales billion swiss francs local sales growth pharmaceuticals division primarily driven six products avastin mabtherarituxan herceptin lucentis actemraroactemra xeloda products represent portfolio together generated billion swiss francs additional sales compared sales products declined contribution sales growth renal anemia medication mircera could fully offset lower sales products due generic erosion following patent expiry voluntary withdrawal raptiva us market roche finance report roche group financial review pharmaceuticals division sales top products sales change product mchf sales local currencies franchise avastin oncology mabtherarituxan oncologyiat herceptin oncology pegasys virology lucentis ophthalmology xeloda oncology tarceva oncology cellcept iat neorecormonepogin renal anemia oncology bonvivaboniva metabolismbone tamiflu virology xolair respiratory diseases valcytecymevene virology pulmozyme respiratory diseases activasetnkase cardiovascular diseases nutropin metabolismbone actemraroactemra iat xenical metabolismbone neutrogin oncology rocephin infectious diseases total top products products total inflammationautoimmunetransplantation avastin sales advanced colorectal breast lung kidney cancer relapsed glioblastoma type brain tumour rose local currencies billion swiss francs reflecting continued positive uptake product overall sales growth western europe driven primarily continued uptake breast cancer improved uptake lung cancer us sales stable overall lower sales second half reflecting regulatory reimbursement uncertainty regarding metastatic breast cancer indication strong sales growth japan driven good uptake colorectal cancer nonsmall cell lung cancer significant sales growth also recorded latin america following marketing approval china earlier year avastin launched firstline treatment metastatic colorectal cancer third quarter contributed sharp growth sales asia mabtherarituxan fullyear sales oncology autoimmune disease areas nonhodgkins lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis ra totalled billion swiss francs increase local currencies versus sustained growth oncology segment driven uptake cll continued strong use nhl western europe us high growth international region including increases key emerging markets reflects uptake medicine nhl indications european rollout mabthera new indication firstline maintenance treatment patients follicular lymphoma began fourth quarter estimated sales ra segment reached billion swiss franc mark growth driven increased use patients inadequate response one tumour necrosis factor inhibitors growing acceptance six month repeat treatment intervals herceptin global sales herpositive breast cancer advanced herpositive stomach cancer rose local currencies billion swiss francs due sustained growth united states western europe significant increase international region herceptin maintained solid market penetration breast cancer sales also benefiting initial uptake stomach cancer eu countries markets addition improvements quality testing expanding population patients eligible treatment herceptin higher sales volume japan outweighed effect revised reimbursement prices april resulting significant decline sales compared pegasys sales hepatitis b c remained virtually stable yearonyear billion swiss francs growth seen asia region sales decreases western europe japan offset growth international region especially asia cemai countries products market share continued expand main european markets us japan global sales continued benefit clinical data reinforcing superiority pegasys hepatitis c treatment options increased use treatment hepatitis b lucentis us sales wet agerelated macular degeneration macular edema following retinal vein occlusion grew local currencies billion swiss francs strong growth throughout year driven primarily increase total number patients receiving lucentis time patients treatment us launch lucentis treatment macular edema swelling retina following retinal vein occlusion began late june initial uptake encouraging xeloda sales colorectal stomach breast cancer rose local currencies billion swiss francs growth driven primarily significant increases united states japan china products three largest markets global sales xeloda benefitting number new indications including stomach cancer china expanded metastatic colorectal cancer indication japan adjuvant colon cancer europe well increased patient share metastatic breast cancer eu tarceva sales advanced lung pancreatic cancer grew local currencies billion swiss francs driven mainly increased use secondline nonsmall cell lung cancer setting main growth contributions came international region growth also japan united states growth us reflects steady demand lung pancreatic cancer indications impact government healthcare reforms background stable demand sales western europe declined slightly mainly result governmentmandated pharmaceutical price reductions rebates several major markets sustained sales growth japan reflects continued market penetration oncologists increasing confidence benefits treatment tarceva cellcept billion swiss francs sales cellcept prevention solid organ transplant rejection remained significant sales decrease local currencies due loss patent exclusivity united states may resulting losses competition generic versions caused us sales decrease partly offset sales growth international region japan neorecormonepogin combined sales roches neorecormon chugais epogin epoetin beta declined local currencies billion swiss francs roches overall share european anemia market remained stable despite increasing biosimilars competition due mainly strong performance mircera major eu countries robust market share volume neorecormon renal indication decline sales epogin japan mainly due competition dialysis market lower national health insurance reimbursement price effects outweighed increased demand medicine predialysis segment roche finance report roche group financial review tamiflu following unprecedented demand due influenza hn pandemic sales tamiflu influenza b totalled billion swiss francs decrease billion swiss francs lower government stockpiling orders largely completed early influenza hn pandemic passing peak sales fell sharply last three quarters sales also affected relatively mild influenza seasons hemispheres actemraroactemra global rollout novel rheumatoid arthritis medicine actemra continued sales totalled million swiss francs rise local currencies uptake actemraroactemra eu united states launch markets remains encouraging continued strong sales growth japan reflects increasing use actemra firstline biologic mircera sales renal anemia medication mircera rose local currencies million swiss francs demand mircera available countries worldwide coming mainly predialysis segment new patient commencements see business report part annual report information roches pharmaceutical products sales region worldwide pandemic hn influenza virus swine flu outbreak began first half pandemic sales resulted unusually high sales tamiflu comparative period significant decline demand since december led varying impacts across regions shown table therefore following comments focus business excluding tamiflu united states sales continued grow local currencies driven oncology products lucentis covered substantial decline cellcept post patent expiry us dollars negative impact regional sales growth percentage points addition initial impact us healthcare reforms led reduction sales approximately million us dollars million swiss francs increased rebates affecting major products sales western europe increased due strong oncology portfolio good uptake actemraroactemra mircera spite estimated million swiss francs negative impact european austerity measures cemai central eastern europe middle east africa central asia indian subcontinent latin america asiapacific regions showed strong growth driven mabtherarituxan herceptin avastin xeloda pegasys mircera sales japan increased continued success avastin actemraroactemra xeloda tarceva mabthera outweighed impact biennial price cuts japan became effective april pharmaceuticals division sales region change sales change excluding tamiflu region mchf sales local currencies local currencies united states western europe japan cemai latin america asiapacific regions total central eastern europe middle east africa central asia indian subcontinent operating results royalties operating income decline local currencies particular due million swiss francs lower income outlicensing agreements decrease mainly due nonrecurrence significant milestone payments glaxosmithkline million swiss francs related orlistat otc approval eu million swiss francs bonvivaboniva milestone income chugai furthermore comparative period included income disposal products mainly latin america million swiss francs compared million swiss francs effects partly offset higher royalty income total royalties operating income percentage sales decreased percentage points pharmaceuticals division royalties operating income change mchf mchf local currencies royalty income income outlicensing agreements income disposal products total ifrs core basis cost sales core basis costs decreased local currencies result lower royalty expenses reductions manufacturing costs lower costs collaboration agreements percentage sales cost sales declined decline manufacturing cost goods sold period costs mainly due productivity improvements favourable product mix effects comparative period includes onetime impact inventory writeoff million swiss francs voluntary withdrawal raptiva us market royalty expenses lower mainly due lower sales tamiflu cellcept partly offset higher royalties bonvivaboniva million swiss francs result contractual change glaxosmithkline expenses collaboration profitsharing agreements decreased reduction primarily result amended agreement glaxosmithkline bonvivaboniva expenses million swiss francs compared million swiss francs expenses collaboration agreements biogen idec novartis osi us increased million swiss francs million swiss francs project termination costs manufacturing logistics area million swiss francs recorded part operational excellence programme amortisation charge marketed products use lower local currencies certain acquisition intangibles fully amortised end pharmaceuticals division cost sales change mchf mchf local currencies manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements restructuring expenses impairment property plant equipment cost sales core basis global restructuring operational excellence amortisation intangible assets total ifrs basis roche finance report roche group financial review marketing distribution core costs declined local currencies billion swiss francs percentage sales remained practically stable sales marketing efforts focussed oncology portfolio rollout additional approved indications avastin herceptin continued rollouts support actemraroactemra rheumatoid arthritis bonvivaboniva pegasys also increased focus emerging markets bad debt provisions increased significantly taking account financial crisis particularly southern europe higher costs compensated generally lower product promotion field force expenses termination costs commercial operations million swiss francs recorded part operational excellence programme pharmaceuticals division marketing distribution change mchf mchf local currencies marketing distribution core basis global restructuring operational excellence total ifrs basis research development increase research development costs seen previous years halted core research development expenses declined local currencies due resource prioritisation securing longterm growth promising pipeline research development costs percentage sales main focus areas metabolism franchise new phase iii initiations requiring smaller studies investments earlierstage neurology portfolio offset lower life cycle investments oncology inflammation research development expenses also included immediate recognition remaining costs million swiss francs necessary cover termination ocrelizumab rheumatoid arthritis development programme payment received novartis opting lucentis study treatment macular edema following retinal vein occlusion majority costs million swiss francs recorded part operational excellence programme relate impairments intangible assets due project terminations million swiss francs termination costs research development million swiss francs remaining impairment charges million swiss francs include million swiss francs respect product intangibles available use primarily due recent clinical data pharmaceuticals division research development change mchf mchf local currencies research development core basis global restructuring operational excellence amortisation intangible assets impairment intangible assets total ifrs basis general administration overall core costs decreased local currencies driven lower administration costs organisational shift effective january certain finance communication functions corporate administration costs million swiss francs percentage points sales functions included results pharmaceuticals division remaining reduction administration costs mainly due synergies following genentech integration noncore costs general administration area included costs million swiss francs relating operational excellence consists mainly employee termination costs effective march group obtained full ownership genentech continued implementation reorganisation groups us pharmaceuticals business announced july subsequently group commenced restructuring pharmaceuticals manufacturing operations particularly biotech network expenses million swiss francs incurred mainly due site closure employeerelated costs comparative period million swiss francs incurred mainly impairment manufacturing facilities additional information given note consolidated financial statements total cost integration restructuring billion swiss francs includes billion swiss francs incurred years total billion swiss francs approximately billion swiss francs noncash legal environmental settlement costs million swiss francs decrease million swiss francs compared costs represent current development various litigation issues additional information given note consolidated financial statements pharmaceuticals division general administration change mchf mchf local currencies administration gains losses divestment businesses restructuring expenses gains losses disposal property plant equipment general items general administration core basis global restructuring operational excellence global restructuring genentech transaction alliances business combinations legal environmental settlements total ifrs basis operating free cash flow pharmaceuticals division generated strong operating free cash flow billion swiss francs percentage sales divisions operating free cash flow decreased compared decrease local currencies compared driven increase net working capital billion swiss francs mainly due payment large yearend accruals included payment employee retentionseverance schemes high royalty payments relating large tamiflu sales second half thirdparty receivables remained end similar level despite higher dayssalesoutstanding levels particularly southern europe operating profit cash adjustments decreased mainly due billion swiss francs impairments property plant equipment following genentech transaction comparative period roche finance report roche group financial review pharmaceuticals division operating free cash flow mchf mchf operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments increase decrease net working capital accounts receivable inventories accounts payable total increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales operating profit cash adjustments include elimination depreciation amortisation impairment charges property plant equipment intangible assets replacement operating incomeexpenses provisions equity compensation plans disposals property plant equipment intangible assets cash equivalents detailed breakdown provided diagnostics operating results diagnostics division increased sales billion swiss francs growing local currencies swiss francs us dollars thereby strengthening leading market position core operating profit increased local currencies swiss francs billion swiss francs core operating profit margin increased percentage points sales driven high sales growth positive effects favourable product mix manufacturing efficiency gains tight management operating expenses exchange rate movements positive percentage point effect margin global restructuring expenses million swiss francs recorded operational excellence development manufacturing activities relating blood gas diagnostics transferred rotkreuz switzerland divisions professional diagnostics business area global headquarters site graz austria closed research development insulin pumps transferred burgdorf switzerland mannheim germany diabetes cares global headquarters addition manufacturing new pumps outsourced burgdorf site closed thereafter diagnostics chemical raw materials manufacturing analytical services germany discontinued mannheim transferred sites diagnostics division acquired micropump specialist medingo thereby broadening portfolio innovative insulin delivery technologies strengthening position diabetes care business tissue diagnostics business area completed acquisition us company bioimagene complement strengthen offering image analysis information management information divisional business pipeline see business report part annual report diagnostics division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales operating profit margin sales operating free cash flow margin sales sales diagnostics business continued increase sales significantly ivd market growth local currencies professional diagnostics sales growth leveraged immuno diagnostics diabetes care sales growth main growth contributors business areas growing respective markets sales molecular diagnostics totalled million swiss francs increase led virology segment applied science sales grew local currencies driven cell analysis genomics custom biotech segments sales tissue diagnostics totalled million swiss francs driven sales advanced tissue staining market diagnostics division sales business area sales change business area mchf sales local currencies professional diagnostics diabetes care molecular diagnostics applied science tissue diagnostics total professional diagnostics sales rose local currencies twice market rate million swiss francs immunoassay business grew gaining additional market share due new placements cobas analysers combined strong assay sales expanding test menu key drivers clinical chemistry growth pointofcare solutions growth professional diagnostics launched eight new nextgeneration immunoassays including six tests diagnose monitor infectious diseases following fda approval september rollout cobas series clinical chemistry modules cobas c cobas c commenced us july new cobas immunoassay module e launched europe countries recognising ce mark october us module improves testing efficiency enabling largevolume laboratories fully consolidate immunoassay clinical chemistry testing roche finance report roche group financial review diabetes care combined sales blood glucose monitoring systems insulin pumps outpaced market rising local currencies million swiss francs main growth drivers accuchek avivaaccuchek performa blood glucose monitoring systems supported continued market uptake accuchek aviva nanoaccuchek performa nano meters stripfree accuchek mobile system eu maltoseindependent test strip chemistries received regulatory approval june immediately rolled us japanese regulatory approvals maltosefree test strip chemistries expected enable latest additions accuchek portfolio launched key markets insulin delivery business posted robust sales growth primarily due accuchek combo combined insulin pump blood glucose monitoring system may diabetes care acquired medingo enhancing portfolio innovative micropump strengthen offering insulin delivery molecular diagnostics sales local currencies increased million swiss francs main contribution virology eastern europe north america asiapacific demand continued fully automated cobas system mid highthroughput laboratories fda approved lightcycler mrsa advanced test dual pcrtarget hiv tests successfully launched us molecular diagnostics received ce mark certification cobas taqscreen dpx test first duplex test enabling simultaneous realtime detection parvovirus b hepatitis virus increased safety human plasma plasma products data athena trial assessing utility cobas hpv test screening cervical cancer presented international papillomavirus conference july data confirmed increased accuracy hpv dna testing including genotyping used file test fda june applied science sales rose local currencies million swiss francs driven strong growth cell analysis genomics custom biotech segments sales magna pure lightcycler product lines sample preparation quantitative pcr analysis declined due dramatically lower demand influenza hn virus testing cell analysis driven full integration innovatis product portfolio continued demand xcelligence systems including recently launched rtca ht instrument highthroughput analysis rtca cardio instrument labelfree cardiotoxicity testing genomics uptake mediumthroughput benchtop gs junior dna sequencer strong enabling nextgeneration sequencing thousands research labs worldwide applied science entered partnership ibm develop thirdgeneration sequencing nanoporebased singlemolecule sequencing tissue diagnostics sales totalled million swiss francs local currencies outperforming market key regions advanced tissue staining immunohistochemistry ihc situ hybridisation ish continued main growth driver reflecting strong reagent sales along continued robust uptake benchmark ultra system simultaneous ihc ish testing single platform tissue diagnostics expanded advanced staining portfolio launching new antibodies support diagnosis various cancers september label sish dna probe extended europe countries recognising ce mark include use assessing likelihood response treatment herceptin breast gastric cancer tissue diagnostics completed acquisition bioimagene leader digital pathology analysis workflow products enabling high resolution wholeslide digital images glass microscope slides see business report part annual report information roches diagnostics products business areas sales regions sales outgrew market regions asiapacific countries led china south korea achieved especially strong growth driven mainly professional diagnostics despite pricing challenges sales growth outperformed market emea europe middle east africa mature emerging economies driven strong performance professional diagnostics diabetes care business areas professional diagnostics tissue diagnostics primary growth drivers north america growth japan good performance professional diagnostics offset continuing challenges diabetes care overall divisional sales grew ahead market increased investments regions well high demand immunoassays leadingedge roche products contributed robust abovemarket growth e brazil russia india china south korea mexico turkey emerging markets sales accounting total divisional sales diagnostics division sales region sales change region mchf sales local currencies emea north america asiapacific latin america japan total europe middle east africa operating results royalties operating income income million swiss francs higher local currencies compared due local currency increases outlicensing income result new pcr license contracts also increase royalty income diagnostics division royalties operating income change mchf mchf local currencies royalty income income outlicensing agreements income disposal products total ifrs core basis cost sales core cost sales increased local currencies growth proportional sales growth resulting lower cost sales ratio compared various cost reduction initiatives centralisation logistics services harmonisation technical services practices renegotiations supplier contracts positive impact compensated higher depreciation installation costs continued investments expand market share meter placements increase installed instrument base part operational excellence programme costs million swiss francs incurred relating manufacturing facilities graz austria rotkreuz burgdorf switzerland mannheim germany total cost sales therefore increased compared roche finance report roche group financial review diagnostics division cost sales change mchf mchf local currencies manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring operational excellence amortisation product intangibles impairment product intangibles total ifrs basis marketing distribution division introduced several major new products initial markets increase local currencies mainly reflects higher costs professional diagnostics tissue diagnostics strong investments made emea asiapacific accelerate growth tissue diagnostics core basis marketing distribution costs percentage sales compared expenses million swiss francs incurred relating operational excellence marketing distribution diagnostics division marketing distribution change mchf mchf local currencies marketing distribution core basis global restructuring operational excellence amortisation intangible assets total ifrs basis research development core costs declined local currencies result tight cost control particular professional diagnostics applied science molecular diagnostics percentage sales research development costs decreased major programmes included athena hpv trial development maltose independent chemistry blood glucose meters expenses million swiss francs incurred relating operational excellence research development described graz austria rotkreuz burgdorf switzerland diagnostics division research development change mchf mchf local currencies research development core basis global restructuring operational excellence amortisation intangible assets impairment intangible assets total ifrs basis general administration core general administration costs decreased local currencies due lower restructuring expenses percentage sales costs declined percentage points diagnostics division general administration change mchf mchf local currencies administration restructuring expenses gains losses disposal property plant equipment general items general administration core basis global restructuring operational excellence alliances business combinations legal environmental settlements total ifrs basis operating free cash flow operating free cash flow diagnostics division million swiss francs increased local currencies compared strong increase operating profit partially offset increases net working capital increase net working capital million swiss francs primarily due increases accounts receivable especially certain european countries greece higher inventory levels resulting launch key products percentage sales operating free cash flow diagnostics division increased compared diagnostics division operating free cash flow mchf mchf operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments increase decrease net working capital accounts receivable inventories accounts payable total increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales operating profit cash adjustments include elimination depreciation amortisation impairment charges property plant equipment intangible assets replacement operating incomeexpenses provisions equity compensation plans disposals property plant equipment intangible assets cash equivalents detailed breakdown provided roche finance report roche group financial review corporate operating costs general administration core basis costs higher local currencies million swiss francs million swiss francs mainly due new group organisation effective january since beginning administration costs include certain finance communication functions previously part pharmaceuticals division costs million swiss francs operating free cash flow net outflow million swiss francs net outflow million swiss francs driven higher operating expenses total costs ifrs basis grew local currencies million swiss francs million swiss francs lower rate core costs operational excellence restructuring expenses million swiss francs significantly lower compared last years increase environmental provisions corporate general administration change mchf mchf local currencies administration restructuring expenses general items general administration core basis global restructuring legal environmental settlements total ifrs basis foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported local currencies swiss francs change local currencies change chf sales core operating profit exchange rates swiss franc december average december average usd eur jpy average rates euro us dollar many currencies lower swiss franc compared yen currencies strengthened swiss franc sales developments resulted growth percentage points lower swiss franc terms compared local currency basis core operating profit growth expressed swiss francs percentage point lower local currencies slightly higher impact due different currency structure operating costs sales sensitivity group sales core operating profit absolute terms movement foreign currencies swiss franc shown table currency sensitivities impact rise average exchange sales core operating profit rate versus swiss franc mchf mchf us dollar euro japanese yen currencies nonoperating results nonoperating results core basis change mchf mchf chf operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests nonoperating results ifrs basis change mchf mchf chf operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche finance report roche group financial review results include full twelve months interest expenses new debt issued finance genentech transaction compared nine months increase fullyear effect partly offset lower interest expenses due repayment bonds notes also million swiss francs recorded loss early redemption debt financing costs therefore increased million swiss francs million swiss francs exceeding financial income million swiss francs addition comparative period included noncore financing costs million swiss francs directly attributable genentech transaction groups effective tax rate core basis decreased slightly compared net income increased driven strong operating performance spite significantly lower tamiflu sales overall lower noncore items global restructuring charges amortisation impairment intangible assets although significant charges already incurred respect operational excellence initiative core basis net income decreased slightly core net income attributable roche shareholders higher compared due improving operating performance elimination noncontrolling interests compensating higher financing costs arising genentech transaction net financial result core basis millions chf financing costs financial income net financial result financial income financial income million swiss francs declining compared interest income income debt securities million swiss francs due decreases interest rates reduced debt security holdings net foreign exchange result loss million swiss francs compared gain million swiss francs decline mainly due currency devaluation venezuela net income equity securities million swiss francs compared million swiss francs expected returns pension plan assets million swiss francs compared due increases value pension plan assets order execute genentech transaction group liquidated certain debt securities cash resulted noncore net loss million swiss francs included ifrs financial income full analysis financial income given note consolidated financial statements financing costs financing costs million swiss francs increase million swiss francs compared increase mainly due million swiss francs loss early redemption debt group redeemed september billion us dollars notes due march exercised option call redemption billion us dollars notes due march interest expenses million swiss francs increase million swiss francs reflecting twelve months financing costs compared nine months debt issued connection genentech transaction partly offset lower interest expenses following repayment early redemption bonds notes interest cost pension plans million swiss francs remained stable due prevailing financial conditions first quarter group issued bonds notes advance genentech transaction totalling billion swiss francs series debt offerings noncore interest expense instruments bridging period issue completion genentech transaction march million swiss francs included ifrs financing costs full analysis financing costs given note consolidated financial statements income taxes groups effective tax rate core basis decreased slightly percentage points reduction mainly due three month additional interest costs debt raised finance genentech transaction losses early redemption bonds tax deductible us tax benefit million swiss francs recorded noncore items described compared tax benefit million swiss francs primarily due lower global restructuring costs recorded well impact income taxes equity compensation plans analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf groups effective tax rate core basis global restructuring intangible assets groups effective tax rate ifrs basis roche finance report roche group financial review net income earnings per share net income attributable roche shareholders billions chf core eps chf groups net income increased billion swiss francs compared increase due strong operating performance spite significantly lower tamiflu sales overall lower noncore items global restructuring charges amortisation impairment intangible assets excluding noncore items core net income decreased slightly portion attributable roche shareholders rose ifrs net income attributable roche shareholders rose billion swiss francs comparative period included million swiss francs attributable genentech noncontrolling interests march genentech transaction positive impact net income attributable roche shareholders earnings per share synergy savings elimination allocation noncontrolling interests compensate costs financing transaction diluted eps chf chf change ifrs basis core increase diluted eps due increase net income attributable roche shareholders described core eps excludes noncore items global restructuring charges amortisation impairment intangible assets increased swiss francs local currencies supplementary net income eps information given pages includes calculations core eps reconciles groups published ifrs results cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow pharmaceuticals diagnostics corporate group mchf mchf mchf mchf operating profit operating profit cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating profit operating profit cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating profit cash adjustments include elimination depreciation amortisation impairment charges property plant equipment intangible assets replacement operating incomeexpenses provisions equity compensation plans disposals property plant equipment intangible assets cash equivalents detailed breakdown provided free cash flow group billion swiss francs compared billion swiss francs decrease billion swiss francs driven higher interest dividend payments nonrecurrence onetime tax benefits increase net working capital following settlement unusually high accruals end although operating profit increased operating free cash flow decreased billion swiss francs mainly caused increases net working capital billion swiss francs particular due payments certain large yearend accruals notably tamiflu royalties employee retention severance schemes capital expenditure property plant equipment included investments new pharmaceuticals research production facilities switzerland germany united states operating profit cash adjustments decreased billion swiss francs billion swiss francs mainly due large noncash items genentech integration first quarter large interest payments made new debt issued comparable payments first quarter debt single annual interest payment first quarter year main reason decrease free cash flow treasury activities billion swiss francs resulting overall outflow billion swiss francs total taxes paid billion swiss francs higher comparative period total tax payments unusually low due onetime billion swiss francs tax benefit settlement stock options genentech employees upon closing genentech transaction march roche finance report roche group financial review total dividends paid billion swiss francs increase billion swiss francs compared reflecting increase roche group dividend year net debt millions chf december cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period free cash flow transactions equity instruments business combinations net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period net debt position group billion swiss francs end decrease billion swiss francs december mainly due free cash flow billion swiss francs described outflow billion swiss francs came mainly transactions equity instruments executed cover exposure equity compensation plans issued employees addition billion swiss francs paid business combinations mainly marcadia net debt position improved also due translation gain billion swiss francs consolidation total debt groups us affiliates due stronger swiss franc compared us dollar improvement partially offset payments group billion swiss francs hedging collateral arrangements set following financing genentech transaction see group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar total exposure hedged issuance bonds notes approximately billion swiss francs see note consolidated financial statements collateral agreements entered derivative counterparties mitigate counterparty risk fair value derivative instruments went due strengthening us dollar euro cash collateral billion swiss francs delivered roche decreased december cash collateral balance favour roche billion swiss francs billion swiss francs december collateral balance relation hedges nonus dollardenominated bonds notes mainly sensitive foreign exchange rate us dollar euro also swiss franc pound sterling currently collateral balance moves approximately million us dollars foreign exchange rates move simultaneously collateral volatility decrease less million us dollars movement foreign exchange rates mid nonus dollardenominated bonds notes repaid realised loss derivatives billion swiss francs relates mainly hedges nonus dollar denominated bonds notes redemption due dates billion us dollar billion euro floating rate notes billion us dollar genentech senior notes early redemption notes september principal value billion us dollars due march main factors decline billion swiss francs liquid funds however impact net debt position balance sheet balance sheet billions chf capitalisation billions chf liabilities assets debt plus equity condensed balance sheet december december mchf mchf change property plant equipment goodwill intangible assets noncurrent assets cash marketable securities current assets total assets debt current noncurrent noncurrent liabilities current liabilities total liabilities total net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity debt equity capitalisation full consolidated balance sheet given consolidated financial statements noncurrent assets property plant equipment declined particular due impairments result operational excellence announcements regarding site closures diagnostics austria switzerland due euro us dollar significantly weakening respectively swiss franc goodwill intangible assets also declined driven amortisation impairments weaker euro majority impairments intangible assets results portfolio prioritisation decisions part operational excellence initiative roche finance report roche group financial review current assets accounts receivable inventories increased moderately local currencies weakening euro impact overall balances swiss francs carrying value derivative assets decreased billion swiss francs consistent decrease carrying value debt hedging cash marketable securities declined described cash flows net debt commentary debt carrying value debt mainly financing genentech transaction decreased billion swiss francs reduction reflects redemption due dates billion us dollar billion euro floating rate notes billion us dollar genentech senior notes early redemption september billion us dollars notes due march detailed reconciliation debt movements provided note consolidated financial statements noncurrent current liabilities overall balance decreased billion swiss francs mainly due repayment billion swiss francs collateral payable fair value derivatives declined addition accounts payable accrued liabilities decreased billion swiss francs due payment accrued royalties notably respect tamiflu sales second half accrued employee retentionseverance schemes total net assetsequity significant movements equity net income billion swiss francs dividend payments billion swiss francs overall capitalisation total debt plus equity declined debt significantly lower due repayments equity higher net income offset dividend end equity made capitalisation compared year previously debt finance genentech transaction group issued bonds notes equivalent billion swiss francs february march bonds notes raised early roughly already repaid december includes early redemption notes september principal value billion us dollars due march addition december group resolved exercise option call redemption portion us dollar fixed rate notes due march total principal amount billion us dollars billion us dollars redeemed march portion notes shown due table maturity schedule groups bonds notes outstanding december shown table includes instruments already issue prior genentech transaction bonds notes nominal amounts december contractual maturity us dollar euro uk sterling swiss franc principal principal principal principal total total musd meur mgbp mchf musd mchf beyond total total translated december exchange rates proceeds bonds notes swapped us dollars therefore financial statements bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated ongoing business free cash flow billion swiss francs includes cash generated operations well payment interest tax dividends second half free cash flow inflow billion swiss francs first half free cash flow outflow billion swiss francs included billion swiss francs used payment annual dividend shortterm financing requirements group commercial paper programme united states issue billion us dollars unsecured commercial paper notes committed credit lines billion euros million us dollars available backstop lines commercial paper notes totalling billion us dollars outstanding december longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors moodys facilitate efficient access international capital markets described commentary net debt position group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar time collateral agreements entered derivative counterparties mitigate counterparty risk pensions postemployment benefits postemployment benefit plans classified defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swiss francs million swiss francs plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising funding asset management groups various defined benefit plans overseen corporate level plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources roche finance report roche group financial review funding status defined benefit pension postemployment benefit plans mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation funding status overall funding status groups defined benefit plans stable main movements came increase fair value plan assets recovered offset increase defined benefit obligation arising decrease discount rates group continues closely monitor funded status major pension funds addition cash injections group initiated plan changes several local pension plans example major pension funds removing early retirement incentives group continues introduce flexible retirement models anticipation ageing workforce expenses recorded income statement total pension expenses relating groups defined benefit plans million swiss francs compared million swiss francs decrease primarily due higher expected return plan assets arising mainly consequence higher asset base start addition curtailment gains million swiss francs compared million swiss francs based revised actuarial assumptions end total pension expenses expected broadly stable compared excluding curtailment effects full details groups pensions postemployment benefits given note consolidated financial statements roche securities share price market capitalisation december change share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group healthcare companies listed terms total shareholder return tsr ie share price growth plus dividends measured swiss francs actual exchange rates yearend return roche share roche nonvoting equity security combined performance share nonvoting equity security compared weighted average return peer group actual exchange rates peer group abbott laboratories amgen astellas astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer roche sanofiaventis takeda total shareholder return development dec march june sept dec roche share roche gs peer set index proposed dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments shares nonvoting equity securities issue amount billion swiss francs billion swiss francs resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given pages finance report information per share nonvoting equity security chf chf change basic eps diluted eps core eps equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements pages finance report payout ratio calculated dividend per share divided core earnings per share roche finance report roche group financial review financial risks december group net debt position billion swiss francs december billion swiss francs financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements roche reduced money market portfolio billion swiss francs instruments matured sold cash marketable securities mchf total mchf total cash cash equivalents money market instruments bonds debentures investments shares total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups billion swiss francs fixed income marketable securities remained strong invested aaaa range noted previously group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables billion swiss francs since beginning year increasing financial difficulties certain southern european countries particularly greece group leading supplier greek healthcare sector trade receivables greek public customers second half group accepted offer made greek government settle large parts trade receivables zero coupon government bonds redeemable first government bonds received late december group expects receive remaining government bonds first half group carefully monitoring situation assessing options manage counterparty exposures bad debt provisions increased reflect various developments liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years despite total debt billion swiss francs december roche enjoys strong longterm investmentgrade credit ratings aa standard poors moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling billion swiss francs december billion swiss francs billion swiss francs serve backstop line commercial paper programme december debt drawn credit lines market risks market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices var data table indicates economic loss level period one month probability exceeded actual future economic gains losses associated treasury activities may differ materially var analyses performed due inherent limitations associated predicting timing amount changes interest rates foreign currency exchanges rates equity investment prices particularly periods high market volatilities furthermore var numbers include credit risk component market risk financial instruments december december mchf mchf var interest rate component var foreign exchange component var price component diversification var total december total var financial assets liabilities million swiss francs december million swiss francs interest rate var decreased million swiss francs reflecting ageing debt repayment debt higher duration fixed income assets held issued debt held amortised cost interest rate var sole metric economic fair value changes impact carrying value profit loss group foreign exchange var basically remained stable price risk arises mainly movements prices equity securities declined equity securities holdings reduced december group held equity securities market value billion swiss francs december billion swiss francs includes holdings biotechnology companies acquired context licensing transactions scientific collaborations information financial risk management financial risks var methodology included note consolidated financial statements international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group early adopted revised versions ifrs business combinations ias consolidated separate financial statements required implemented january latest group also implemented various amendments existing standards interpretations material impact groups overall results financial position roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf disclosed note income statement restated following accounting policy changes adopted reconciliation previously published income statement provided note roche finance report roche group roche group consolidated financial statements roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets associates financial longterm assets longterm assets deferred income tax assets postemployment benefit assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefit liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche finance report roche group roche group consolidated financial statements roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital payments made defined benefit postemployment plans utilisation provisions disposal products operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations divestments subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements change ownership interest subsidiaries genentech memory equity contribution noncontrolling interests interest paid dividends paid genentech equity compensation plans equitysettled equity compensation plans net transactions equity instruments chugai share repurchases financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december disclosed note statement cash flows restated following accounting policy changes adopted change disposal products totalling million swiss francs reported operating rather investing cash flows roche group consolidated statement changes equity millions chf reserves non share retained fair controlling total capital earnings value hedging transl ation total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans total comprehensive income business combinations dividends paid equity compensation plans net transactions equity instruments chugai share repurchases changes ownership interests subsidiaries genentech memory changes noncontrolling interests december year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans total comprehensive income dividends paid equity compensation plans net transactions equity instruments changes noncontrolling interests equity contribution noncontrolling interests movements december roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors january subject approval annual general meeting shareholders march preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change changes accounting policies arise application new revised standards interpretations applied retrospectively unless otherwise specified transitional requirements particular standard interpretation retrospective application requires results comparative period opening balances period restated new accounting policy always applied cases transitional requirements particular standard interpretation specify changes applied prospectively prospective application requires new accounting policy applied results current period comparative period restated addition comparatives reclassified extended previously reported results take account presentational changes consolidation policy financial statements consolidated financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enterprise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights currently exercisable potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled group companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control investments associates accounted using equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights currently exercisable potential voting rights company balances transactions associates result unrealised income eliminated extent groups interest associate interests joint ventures reported using linebyline proportionate consolidation method segment reporting determination groups operating segments based organisation units information reported groups management group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenue sale licensing products technology third parties certain headquarter activities reported corporate consist corporate headquarters including corporate executive committee corporate communications corporate human resources corporate finance including treasury taxes pension fund management corporate legal corporate safety environmental services subdivisional information roche pharmaceuticals chugai previously aggregated operating segments within pharmaceuticals division also presented transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation group companies use local currency functional currency certain group companies use currencies us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred equity upon consolidation assets liabilities group companies using functional currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity disposal foreign entity identified cumulative currency translation differences within equity relating foreign entity recognised income part gain loss divestment roche finance report roche group notes roche group consolidated financial statements revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid united states similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients revenues recorded earned services performed necessary single transactions split separately identifiable components reflect substance transaction conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profit sharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research costs costs incurred purpose gaining new scientific technical knowledge understanding costs expensed incurred internal development costs costs incurred application research findings knowledge plan develop new products commercial production costs would qualify capitalisation intangible assets following criteria demonstrated technical feasibility completing development project successfully available use sale intention complete development project ability use sell results development project development project would generate economic benefits would normally evidenced existence size market results project products would result project availability adequate technical financial resources complete development project ability measure development expenditure reliably would qualify capitalisation intangible asset development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation met prior obtaining marketing approval regulatory authorities major markets internal development costs meet criteria therefore expensed incurred postmarketing studies regulatory approval phase iv costs pharmaceuticals business expensed incurred generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons safety surveillance designed detect rare long term adverse effects much larger patient population longer time period possible earlier stages development costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured addition internal research development activities group also party inlicensing similar arrangements alliance partners group may also acquire inprocess research development assets either business combinations purchases specific assets inprocess research development resources acquired either inlicensing arrangements business combinations separate purchases capitalised intangible assets controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy reviewed impairment set impairment property plant equipment intangible assets policy available use intangible assets amortised straightline basis period expected benefit reviewed impairment reporting date research development embedded contracts strategic alliances group carefully assess whether upfront milestone payments constitute funding research development work acquisition asset licensing milestone upfront receipts royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive third parties upfront milestone similar payments relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned liabilities longterm employee benefits discounted take account time value money material pensions postemployment benefits employees covered defined benefit defined contribution postemployment plans sponsored group companies groups contributions defined contribution plans charged appropriate income statement heading within operating results year relate accounting reporting defined benefit plans based recent actuarial valuations defined benefit obligations service costs calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth long term expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned past service costs allocated average period benefits become vested current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses consist differences assumptions actual experiences effects changes actuarial assumptions recorded directly equity pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative roche finance report roche group notes roche group consolidated financial statements unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly equity equity compensation plans certain employees group participate equity compensation plans including separate plans genentech prior genentech transaction chugai fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity cashsettled plans liability recorded measured fair value reporting date movements fair value recorded appropriate income statement heading within operating results subsequent cash flows exercise vested awards recorded reduction liability property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful life assets regularly reviewed necessary future depreciation charge accelerated repairs maintenance costs expensed incurred leases group lessee leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt assets acquired finance leases depreciated accordance groups policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease group lessor primarily occurs diagnostics division assets subject finance leases initially reported receivables amount equal net investment lease assets subject operating leases reported within property plant equipment lease income finance leases subsequently recognised earned income term lease based effective interest rate method lease income operating leases recognised lease term straightline basis business combinations goodwill business combinations accounted using acquisition method accounting consideration transferred business combination measured fair value date acquisition consideration includes cash paid plus fair value date exchange assets given liabilities incurred assumed equity instruments issued group fair value consideration transferred also includes contingent consideration arrangements fair value directly attributable acquisitionrelated costs expensed current period reported within general administration expenses date acquisition group recognises identifiable assets acquired liabilities assumed non controlling interest acquired business identifiable assets acquired liabilities assumed initially recognised fair value group acquire ownership acquired business noncontrolling interests recorded proportion fair value acquired net assets attributable noncontrolling interest goodwill recorded surplus consideration transferred groups interest fair value acquired net assets goodwill fair value adjustments recorded assets liabilities acquired business functional currency business initial accounting business combination incomplete end reporting period provisional amounts used measurement period provisional amounts retrospectively adjusted additional assets liabilities may recognised reflect new information obtained facts circumstances existed acquisition date would affected measurement amounts recognised date known measurement period exceed twelve months date acquisition goodwill amortised assessed possible impairment reporting date additionally tested annually impairment goodwill may also arise upon investments associates surplus cost investment groups share fair value net identifiable assets goodwill recorded within investments associates changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination fair value allocated acquisition accounting intangible assets amortised useful lives straightline basis beginning point available use estimated useful life lower legal duration economic useful life estimated useful life intangible assets regularly reviewed impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy impairment goodwill goodwill assessed possible impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units described note recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss methodology used impairment testing described note roche finance report roche group notes roche group consolidated financial statements inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded difference carrying value recoverable amount objective evidence group able collect amounts due trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience longterm accounts receivable discounted take account time value money material cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used statement cash flows provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign currency effects arising translation functional currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available fair value hierarchy valuation techniques incorporate observable market data market conditions factors likely affect fair value financial instrument valuation techniques typically used derivative financial instruments fair values financial assets liabilities reporting date materially different reported carrying values unless specifically mentioned notes consolidated financial statements information fair value hierarchy included note risk management financial assets financial assets principally investments including marketable securities classified either fairvalue throughprofitorloss availableforsale heldtomaturity loans receivables fairvaluethrough profitorloss financial assets either classified heldfortrading designated upon initial recognition heldfortrading financial assets acquired principally generate profit shortterm fluctuations price financial assets designated fairvaluethroughprofitorloss results relevant information eliminating measurement recognition inconsistency heldtomaturity financial assets securities fixed maturity group intent ability hold maturity loans receivables financial assets created group acquired issuer primary market nonderivative financial assets fixed determinable payments quoted active market financial assets considered availableforsale financial assets initially recorded fair value including transaction costs except assets fair valuethroughprofitorloss exclude transaction costs purchases sales recognised settlement date fairvaluethroughprofitorloss financial assets subsequently carried fair value changes fair value recorded financial income period arise heldto maturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded equity except interest calculated using effective interest rate method foreign exchange components availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised equity included financial income current period loans receivables subsequently carried amortised cost using effective interest rate method financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity securities market value original cost net previous impairment considered impaired availableforsale equity securities market value original cost net previous impairment sustained sixmonth period also considered impaired decreases market price less original cost net previous impairment also less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity objective evidence impairment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried equity difference original cost net previous impairment fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly equity financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred interest transferred financial assets created retained group recognised separate asset liability derivatives derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments discussed hedging policy changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract host contract carried amortised cost hedge accounting purposes hedge accounting hedging relationships may three types fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedge net investment foreign operation hedge foreign currency exposure net investment foreign operation roche finance report roche group notes roche group consolidated financial statements qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence cash flow hedges hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion reported financial income hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial asset liability cumulative changes fair value hedging instrument recorded equity included initial carrying value asset liability date recognition qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income hedging instrument derivative equity cases entity disposed cumulative changes fair value hedging instrument recorded equity reclassified income debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method group derecognises financial liability contractual obligations discharged cancelled expired certain debt instruments designated fairvaluethroughprofitorloss results relevant information eliminates significantly reduces measurement recognition inconsistencies debt instruments reported fair value based quoted prices active market movements fair value reported within financial income groups last instrument redeemed july disclosed note taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future deferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates discontinued businesses noncurrent assets held sale discontinued business component groups business represents separate major line business geographical area operations subsidiary acquired exclusively view resale reclassification discontinued business occurs upon disposal operation meets criteria classified held sale earlier disposal group group assets disposed group single transaction together liabilities directly associated assets transferred transaction assets liabilities disposal group reclassified held sale value recovered principally sale rather continuing use disposal group must available sale current condition sale must highly probable immediately classification held sale measurement assets liabilities disposal group updated accordance applicable accounting policies initial classification held sale disposal groups recognised lower carrying value fair value less costs sell impairment losses initial classification held sale included income statement equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet potential obligations employees may arise respect certain groups equity compensation plans management judgements made applying accounting policies application groups accounting policies may require management make judgements apart involving estimates significant effect amounts recognised consolidated financial statements management judgement particularly required assessing substance transactions complicated structure legal form include limited following areas revenue recognition nature groups business many sales transactions simple structure sales agreements may consist multiple components occurring different times group also party various outlicensing agreements involve upfront milestone payments may occur several years agreements may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement roche finance report roche group notes roche group consolidated financial statements consolidation subsidiaries associates group periodically undertakes transactions may involve obtaining right control significantly influence operations companies transactions include acquisition part equity companies purchase certain assets assumption certain liabilities contingent liabilities companies entering alliance agreements companies also included transactions involving special purpose entities similar vehicles cases management makes assessment whether group right control significantly influence companys operations based assessment company consolidated subsidiary associated company making assessment management considers underlying economic substance transaction contractual terms business combinations group acquires control another business consideration transferred allocated identifiable assets acquired liabilities assumed non controlling interest acquired business residual recorded goodwill process involves management making assessment fair value items management judgement particularly involved recognition measurement following items intellectual property may include patents licences trademarks similar rights currently marketed products also rights scientific knowledge associated projects currently research development phases contingencies legal environmental matters contingent consideration arrangements recoverability accumulated tax losses previously incurred acquired company cases management makes assessment based underlying economic substance items concerned contractual terms order fairly present items leases group party leasing arrangements lessee lessor treatment leasing transactions financial statements mainly determined whether lease considered operating lease finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments key assumptions sources estimation uncertainty preparation consolidated financial statements conformity ifrs requires management make estimates assumptions affect application policies reported amounts assets liabilities income expenses related disclosures estimates underlying assumptions based historical experience various factors believed reasonable circumstances results form basis making judgements carrying values assets liabilities readily apparent sources actual results may differ estimates estimates underlying assumptions reviewed ongoing basis changes accounting estimates may necessary changes circumstances estimate based result new information experience changes recognised period estimate revised key assumptions future key sources estimation uncertainty significant risk causing material adjustment carrying value assets liabilities within next twelve months described revenue recognition circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients order estimate management uses publicly available information prescriptions well information provided wholesalers intermediaries sales allowances group provisions accruals expected sales returns chargebacks rebates including medicaid united states similar rebates countries december total million swiss francs estimates based analyses existing contractual legislativelymandated obligations historical trends groups experience management believes total provisions accruals items adequate based upon currently available information deductions based management estimates may subject change better information becomes available changes arise could impact provisions accruals recognised balance sheet future periods consequently level sales recognised income statement future periods property plant equipment intangible assets including goodwill group property plant equipment carrying value million swiss francs disclosed note goodwill carrying value million swiss francs see note intangible assets carrying value million swiss francs see note assets reviewed annually impairment described assess whether impairment exists estimates made future cash flows expected result use asset eventual disposal actual outcomes could vary significantly estimates discounted future cash flows factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment changes discount rates used could also lead impairments pensions postemployment benefits many groups employees participate post employment defined benefit plans calculations recognised assets liabilities plans based upon statistical actuarial calculations particular present value defined benefit obligation impacted assumptions discount rates used arrive present value future pension liabilities assumptions future increases salaries benefits furthermore groups independent actuaries use statistically based assumptions covering areas future withdrawals participants plan estimates life expectancy december present value groups defined benefit obligation million swiss francs funded plans million swiss francs unfunded plans see note actuarial assumptions used may differ materially actual results due changes market economic conditions higher lower withdrawal rates longer shorter life spans participants changes factors assessed differences could impact assets liabilities recognised balance sheet future periods legal provisions group companies party various legal proceedings including claims arising trade significant matters described note legal provisions december total million swiss francs management believes total provisions legal proceedings adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued additional claims could made might covered existing provisions insurance assurance increase scope matters future lawsuits claims proceedings investigations material changes arise could impact provisions recognised balance sheet future periods roche finance report roche group notes roche group consolidated financial statements environmental provisions group provisions environmental remediation costs december total million swiss francs disclosed note material components environmental provisions consist costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites future remediation expenses affected number uncertainties include limited detection previously unknown contaminated sites method extent remediation percentage problematic materials attributable group remediation sites relative attributable parties financial capabilities potentially responsible parties management believes total provisions environmental matters adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued effect resolution environmental matters results operations predicted due uncertainty concerning amount timing future expenditures changes arise could impact provisions recognised balance sheet future periods income taxes december net liability current income taxes million swiss francs net asset deferred income taxes million swiss francs disclosed note significant estimates required determine current deferred assets liabilities income taxes estimates based interpretations existing tax laws regulations management believes estimates reasonable recognised liabilities income taxrelated uncertainties adequate various internal external factors may favourable unfavourable effects income tax assets liabilities factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations future levels research development spending changes overall levels pretax earnings changes arise could impact assets liabilities recognised balance sheet future periods changes accounting policies group early adopted revised versions ifrs business combinations ias consolidated separate financial statements required implemented january latest group implemented various amendments existing standards interpretations material impact groups overall results financial position presentation income statement group made certain presentational changes income statement made light current international industry practice taking account latest regulatory guidance changes applied retrospectively listed term exceptional items longer used financial statements income statement headings major legal cases changes group organisation longer shown separately face income statement income expenses included part general administration disclosure made notes respectively subtotal operating profit exceptional items deleted redundant income statement heading exceptional financing costs longer shown separately face income statement income expenses included part financial income financing costs appropriate disclosure made note income statement heading income taxes exceptional items longer shown separately face income statement income expenses included part income taxes disclosure made note income statement year ended december restated following changes set table restated consolidated income statement year ended december millions chf originally published reclassifications restated sales royalties operating income cost sales marketing distribution research development general administration major legal cases changes group organisation operating profit associates financial income financing costs exceptional financing costs profit taxes income taxes income taxes exceptional items net income improvements ifrs ias statement cash flows group made minor presentational change statement cash flows following implementation improvements ifrs issued april change disposal products totalling million swiss francs reported operating rather investing cash flows statement cash flows year ended december restated accordingly group currently assessing potential impacts new revised standards interpretations effective january beyond group early adopted group anticipate material impact groups overall results financial position roche finance report roche group notes roche group consolidated financial statements operating segment information divisional information millions chf pharmaceuticals diagnostics corporate group revenues external c ustomers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses pharmaceuticals subdivisional information millions chf roche pharmaceuticals pharmaceuticals chugai division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results subdivisional profit elimination interdivisional profit operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses net operating assets millions chf assets liabilities net assets pharmaceuticals diagnostics corporate total operating nonoperating group roche finance report roche group notes roche group consolidated financial statements information geographical area millions chf revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas diagnostics division given pages respectively sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue european union information based members eu december major customers us national wholesale distributor amerisourcebergen corp represented approximately billion swiss francs billion swiss francs groups revenues approximately revenues pharmaceuticals operating segment residual diagnostics segment group also reported substantial revenues us national wholesale distributors cardinal health inc mckesson corp total three customers represented approximately quarter groups revenues genentech effective september roche group acquired majority interest approximately genentech inc biotechnology company united states common stock genentech publicly traded listed new york stock exchange symbol dna december groups interest genentech genentech transaction march roche entered merger agreement genentech pursuant group made successful tender offer purchase shares genentech already owned group usd per share cash genentech transaction result genentech became wholly owned subsidiary group effective march cash consideration purchase public shares including shares issuable genentechs outstanding employee stock option plans payment related fees expenses amounted approximately billion us dollars set table amounts recorded equity change ownership interest subsidiaries genentech transaction usd millions chf millions purchase publicly held shares settlement outstanding employee stock options directly attributable transaction costs total cash consideration income tax effects change ownership interest subsidiaries translated spot rate date transaction march usd chf group financed genentech transaction combination groups funds bonds notes commercial paper group raised net proceeds approximately billion swiss francs series debt offerings described note newly issued debt senior unsecured guaranteed roche holding ltd impacts genentech transaction related reorganisation roches pharmaceuticals business groups results described note roche finance report roche group notes roche group consolidated financial statements chugai effective october roche group chugai completed alliance create leading research driven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements conformity accounting principles generally accepted japan jgaap filed quarterly basis tokyo stock exchange due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone results jgaap basis results chugai consolidated roche group accordance ifrs roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also first right refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement signed may roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea chugai decides requires partner activities agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments armslength basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements armslength basis research collaboration agreements roche chugai entered research collaboration agreements areas smallmolecule synthetic drug research biotechnologybased drug discovery dividends dividends distributed third parties holding chugai shares totalled million swiss francs million swiss francs recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items chugai share repurchases chugai repurchased common shares result groups ownership chugai increased total cash outflow including repurchases fractional shares billion japanese yen million swiss francs share repurchases matters details chugais equity compensation plans given note financial income financing costs financial income millions chf year ended december gains sale equity securities losses sale equity securities dividend income gains losses equity security derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities gain loss liquidation debt securities gains losses debt security derivatives net writedowns impairments longterm loans net interest income income debt securities expected return plan assets defined benefit plans foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total financial income roche finance report roche group notes roche group consolidated financial statements financing costs millions chf year ended december interest expense interest expense incurred newly issued bonds notes bridging period amortisation debt discount gains losses debt derivatives net gains losses redemption repurchase bonds notes net gains losses financial liabilities fairvaluethroughprofitorloss net time cost provisions interest cost defined benefit plans total financing costs net financial income millions chf year ended december financial income financing costs net financial income financial result treasury management financial result pension management net financial income genentech transaction financing costs described note effective march group purchased publicly owned shares genentech usd per share cash total cash consideration transaction including shares issuable genentechs outstanding employee stock option plans payment related fees expenses approximately billion swiss francs order execute transaction group liquidated certain debt securities cash resulted net loss transactions million swiss francs furthermore due prevailing financial conditions group issued bonds notes advance transaction totalling billion swiss francs series debt offerings described note interest expense instruments bridging period issue completion genentech transaction march million swiss francs previously presented exceptional financial costs disclosed note income expenses longer shown separately face income statement included part financial income financing costs appropriate appropriate reclassifications made disclosures note income taxes income tax expenses millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total income expense disclosed note income statement heading income taxes exceptional items longer shown separately face income statement income expenses included part income taxes appropriate reclassifications made disclosures note including restatement reconciliation groups effective tax rate table since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates average expected rate increased compared significant local tax rate changes main operating areas group compared main driver increase comes us relatively higher local tax rate average group rate groups taxable profits us increased significantly resulted increase percentage us contributes overall mix groups profit increased profit made us mainly due lower global restructuring costs us recorded billion us dollars compared billion us dollars offsets increased interest expenses us groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect utilisation previously unrecognised tax losses nontaxable incomenondeductible expenses equity compensation plans research development manufacturing tax credits us state tax impacts differences groups effective tax rate impact equity compensation plans effective tax rate increase benefit mainly due onetime impact accelerated vesting genentech plans increased profit contribution us also results higher us state taxes increases groups effective tax rate income tax benefits recorded respect equity compensation plans varies according price underlying equity million swiss francs million swiss francs excluding accelerated vesting impacts genentech plans income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefits approximately million swiss francs million swiss francs would recorded roche finance report roche group notes roche group consolidated financial statements tax effects comprehensive income millions chf pretax tax aftertax pretax tax aftertax amount benefit amount amount benefit amount availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred income taxes assets liabilities net deferred income tax assets liabilities movements amounts recorded balance sheet current income taxes shown table current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid charged credited income statement current income taxes adjustments recognised current tax prior periods charged credited equity equity compensation plans transactions shareholders currency translation effects net current income tax asset liability december deferred income tax assets recognised tax loss carryforwards extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable mchf tax rate mchf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs movements amounts recorded balance sheet deferred income taxes shown table deferred income taxes movements recognised net assets liabilities millions chf property plant equipment temporary intangible assets differences total year ended december net deferred income tax asset liability january lonza singapore acquisition business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects net deferred income tax asset liability december year ended december net deferred income tax asset liability january marcadia acquisition business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects net deferred income tax asset liability december business combinations acquisitions marcadia effective december group acquired controlling interest marcadia biotech inc marcadia privately owned us company based carmel indiana marcadia biopharmaceutical company focused developing broad portfolio drug candidates treatment diabetes obesity marcadia reported part roche pharmaceuticals operating segment acquisition marcadia allow group integrate marcadias development pipeline research development portfolio marcadias research programmes focus new peptide therapies treatment type diabetes obesity include next generation peptides mar novel compound currently phase development based marcadias unique peptide chemistry technology peptides designed offer patients improved efficacy safety convenience roche finance report roche group notes roche group consolidated financial statements total purchase consideration million swiss francs million swiss francs paid cash million swiss francs arises contingent consideration arrangement payment arrangement based achievement two separate performance milestones may arise range outcomes undiscounted zero million us dollars equivalent million swiss francs december exchange rates liability million swiss francs recognised acquisition date based managements best estimate probability adjusted expected cash outflow arrangement december amount recognised arrangement unchanged based recent management estimates purchase consideration allocated shown table assets liabilities amounts allocated provisional based preliminary information valuations assets liabilities marcadia subject adjustment new information obtained facts circumstances existed acquisition date marcadia acquisition net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use inventories deferred income taxes cash net assets liabilities net identifiable assets goodwill purchase consideration goodwill represents control premium synergies obtained groups existing business none goodwill recognised expected deductible income tax purposes fair value net assets liabilities includes receivables fair value million swiss francs acquisitions effective may group acquired controlling interest medingo ltd medingo majorityowned subsidiary elron group based israel medingo engaged development semidisposable insulin patch pump reported part diagnostics operating segment acquisition broadens groups portfolio innovative insulin delivery technologies strengthens position diabetes care business total purchase consideration million swiss francs million swiss francs paid cash million swiss francs arises contingent consideration arrangement payment arrangement based achievement four separate performance milestones may arise range outcomes undiscounted zero million us dollars equivalent million swiss francs december exchange rates liability million swiss francs recognised acquisition date based managements best estimate probabilityadjusted expected cash outflow arrangement december amount recognised arrangement unchanged based recent management estimates effective september group acquired controlling interest bioimagene inc bioimagene privately owned us company based sunnyvale california bioimagene engaged digital pathology workflow analysis field reported part diagnostics operating segment acquisition complements strengthens groups portfolio image analysis diagnosis total purchase consideration million swiss francs cash minor business combinations diagnostics business total purchase consideration million swiss francs cash combined purchase consideration allocated follows acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use technology intangibles use inventories deferred income taxes cash net assets liabilities net identifiable assets liabilities goodwill purchase consideration goodwill represents control premium synergies obtained groups existing business none goodwill recognised expected deductible income tax purposes fair value net assets liabilities include receivables directly attributable transaction costs million swiss francs incurred acquisitions reported within general administration expenses current period part operating result roche pharmaceuticals diagnostics operating segment million swiss francs roche finance report roche group notes roche group consolidated financial statements acquisitions impact results millions chf revenues inventory amortisation external fair value intangible operating customers adjustment assets profit net income impact reported results marcadia pharmaceuticals division medingo bioimagene minor business combinations diagnostics division group estimated impact results acquisition assumed effective january marcadia pharmaceuticals division medingo bioimagene minor business combinations diagnostics division group figures exclude directly attributable acquisitionrelated costs million swiss francs related acquisitions pharmaceuticals division million swiss francs related acquisitions diagnostics division corresponding tax impacts also excluded figures exclude integration costs million swiss francs related medingo bioimagene corresponding tax impacts also excluded acquisitions net cash outflow millions chf cash consideration cash net cash paid acquired company outflow marcadia acquisitions total acquisitions lonza singapore genentech entered supply agreement manufacture certain genentech products facility construction singapore lonza group ltd lonza genentech committed fund precommissioning production qualification costs facility upon fda licensure genentech committed purchase products successfully manufactured facility period three years commissioning facility genentech also received exclusive option purchase lonzas singapore facility period one year fda licensure purchase price million us dollars genentech also entered loan agreement lonza advance million us dollars lonza construction singapore facility genentech exercised option purchase facility outstanding advances may offset purchase price genentech exercise purchase option advances may offset supply purchases regardless whether purchase option exercised genentech would obliged make milestone payment million us dollars certain performance milestones met facility constructed accounting purposes due nature supply agreement genentechs involvement construction buildings genentech considered owner assets construction period even though funds construct building shell infrastructure costs paid lonza december construction progress totalling million swiss francs capitalised liability financing obligation totalling million swiss francs recorded net million us dollars million swiss francs advanced genentech lonza august genentech singapore pte ltd genentech singapore exercised option purchase ownership lonza biologics singapore pte ltd lonza singapore lonza singapore cell culture biologic manufacturing facility mechanically complete expected produce avastin bevacizumab bulk drug substance litres fermentation capacity located approximately acres option additional acres part integration roches genentechs combined technical operations biotechnology production facilities singapore merged operate name roche singapore technical operations exercise option resultant merger approximately lonza employees joined genentech singapore technical operations total site headcount approximately august previous accounting treatment described construction progress totalling million us dollars million swiss francs capitalised similar liability financing obligation recorded addition million us dollars advanced genentech lonza transaction value million us dollars consists million us dollars singapore facility million us dollars various milestone payments amount million us dollars offset loans previously made genentech lonza net transaction value million us dollars million swiss francs million us dollars million swiss francs cash payments million us dollars million swiss francs accrued milestone payments would made accounting purposes million us dollars million swiss francs allocated settlement existing financing obligation million us dollars million swiss francs acquisition lonza singapore business allocated follows lonza singapore acquisition net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets inventories deferred income taxes cash net assets liabilities net identifiable assets goodwill purchase consideration acquisitions effective january group acquired controlling interest memory pharmaceuticals corp memory publicly owned us company based montvale new jersey listed nasdaq symbol memy memory develops innovative drug candidates treatment debilitating central nervous system cns disorders alzheimers disease schizophrenia memory reported part roche pharmaceuticals operating segment acquisition strengthen groups research development pipeline areas alzheimers disease purchase consideration million swiss francs paid cash roche finance report roche group notes roche group consolidated financial statements minor business combinations diagnostics business total purchase consideration million swiss francs million swiss francs cash million swiss francs contingent consideration arrangement liability million swiss francs recognised acquisition date based managements best estimate time probabilityadjusted expected cash outflow arrangement december amount recognised arrangement reduced zero based recent management estimates time combined purchase consideration allocated follows acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment goodwill intangible assets product intangibles use marketing intangibles product intangibles available use inventories provisions deferred income taxes cash net assets liabilities net identifiable assets liabilities noncontrolling interests goodwill purchase consideration subsequent effective date acquisition january group purchased remaining shares memory held third parties give group interest memory cash consideration million swiss francs recorded equity change ownership interest subsidiaries goodwill represents control premium synergies obtained groups existing business none goodwill recognised expected deductible income tax purposes fair value net assets liabilities includes receivables fair value million swiss francs includes allowance doubtful accounts million swiss francs directly attributable acquisitionrelated costs million swiss francs incurred acquisitions reported within general administration expenses current period part operating result pharmaceuticals operating segment million swiss francs diagnostics operating segment million swiss francs acquisitions net cash outflow millions chf cash consideration cash net cash paid acquired company outflow lonza singapore acquisitions total cash consideration include subsequent payment million swiss francs purchase remaining shares memory held third parties give group interest memory reported financing cash flow statement cash flows within heading change ownership interest subsidiaries contingent consideration arrangements group party certain contingent consideration arrangements arising previous business combination arrangements provisions arrangements recorded part provisions see note set table provisions contingent consideration arrangements millions chf january additional provisions created unused amounts reversed utilised year unwinding discount business combinations marcadia medingo minor business combinations currency translation effects december expected outflow resources within one year one two years two three years three years total global restructuring plans genentech transaction restructuring integration july group announced offer purchase outstanding shares genentech following closing transaction genentechs south san francisco site would become headquarters groups combined pharmaceuticals operations united states july group also announced roches pharmaceuticals business us would close manufacturing operations site nutley new jersey commercial operations would moved genentech research site palo alto california would closed research activities transferred nutley genentech subsequent announcements initial restructuring activities started nutley palo alto sites roche finance report roche group notes roche group consolidated financial statements described note genentech transaction completed effective march following pharmaceuticals division initiated detailed integration programme align genentech business rest roches pharmaceuticals business genentechs south san francisco site established headquarters pharmaceuticals business us including commercial operations us market genentech research early development set autonomous unit genentechs latestage development activities integrated global pharmaceuticals division network integration programme included prioritising projects within shared portfolio eliminating activities either duplicated longer required notably administration function following completion transaction pharmaceuticals division carried detailed reassessment global manufacturing network particular emphasis biotech manufacturing facilities result several manufacturing facilities construction projects discontinued notably bulk drug production unit part site vacaville california impairment charge million swiss francs recorded respect facility previous carrying value billion swiss francs assets carrying value billion swiss francs subsequently transferred facilities continuing use restructuring activities substantially completed end total cost billion swiss francs includes billion swiss francs incurred total billion swiss francs approximately billion swiss francs noncash genentech transaction restructuring integration costs millions chf employeerelated costs termination costs pensions postemployment benefits genentech stock options accelerated vesting expenses retention plans employee benefits employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment site closure costs total site closure costs impairment intangible assets reorganisation expenses total operational excellence november group announced details concerning operational excellence global restructuring plan plan aimed adapting cost structures increasingly challenging market environment achieving significant efficiency productivity gains planned measures enable sustained investment research product development thus strengthen groups longterm innovation capability implementation plans include reducing work force positions worldwide groups current work force next two years planned job reductions occur pharmaceuticals division particularly divisions global sales marketing organisation manufacturing approximately jobs would transferred roche sites positions outsourced third parties combination planned job reductions transfers affect positions overall part plans group intends seek buyers pharmaceuticals division manufacturing sites florence south carolina boulder colorado united states research development sites kulmbach germany madison wisconsin united states plans still preliminary stage sites still operation following comprehensive portfolio review pharmaceuticals division decided discontinue certain activities research early development addition certain product development activities discontinued transferred roche sites third parties result decisions intangible assets carrying value million swiss francs fully written diagnostics division sites graz austria burgdorf switzerland closed impairment charges million swiss francs recorded respect facilities previous carrying value million swiss francs group currently anticipates restructuring activities substantially completed end total cost expected order billion swiss francs includes billion swiss francs already incurred operational excellence restructuring costs millions chf employeerelated costs termination costs pensions postemployment benefits equity compensation plans accelerated vesting expenses employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment environmental remediation costs site closure costs total site closure costs impairment intangible assets reorganisation expenses total roche finance report roche group notes roche group consolidated financial statements classification operational excellence restructuring costs millions chf depreciation amortisation impairment costs total cost sales roche pharmaceuticals diagnostics marketing distribution roche pharmaceuticals diagnostics research development roche pharmaceuticals diagnostics general administration roche pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total employee benefits employee remuneration millions chf wages salaries social security costs defined contribution postemployment plans operating expenses defined benefit postemployment plans equity compensation plans termination costs genentech transaction restructuring integration operational excellence employee benefits employee remuneration included operating results expected return plan assets defined benefit postemployment plans interest cost defined benefit postemployment plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits employee benefits also include million swiss francs expenses related genentech employee retention program charges employee benefits operating results included relevant expenditure line function expected return plan assets interest cost defined benefit plans included part financial income financing costs respectively see note pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising consequently groups postemployment benefit plans classified defined benefit plans purpose financial statements defined contribution plans defined contribution plans typically consist payments employees group funds administered third parties payments group million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions defined benefit plans groups major defined benefit plans located switzerland united states germany united kingdom japan plans usually established trusts independent group funded payments group employees cases notably major defined benefit plans germany plan unfunded group pays pensions retired employees directly financial resources current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses recorded directly equity recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly equity roche finance report roche group notes roche group consolidated financial statements defined benefit plans expenses millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total current service cost past service cost gain loss curtailment gain loss settlement total operating expenses expected return plan assets interest cost total financial income expense total expense recognised income statement funding groups various defined benefit plans overseen corporate level qualified independent actuaries carry valuations regular basis major plans annually reporting date funded plans usually trusts independent groups finances net assetliability recognised groups balance sheet corresponds overunder funding plan adjusted unrecognised past service costs unfunded plans group meets pension obligations directly financial resources liability defined benefit obligation recorded groups balance sheet pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan amounts recognised balance sheet postemployment benefits predominantly noncurrent reported noncurrent assets liabilities defined benefit plans funding status millions chf funded unfunded funded unfunded plans plans total plans plans total fair value plan assets defined benefit obligation funding unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability reported defined benefit plans reimbursement rights postemployment benefit assets postemployment benefit liabilities net recognised asset liability detailed information plan assets defined benefit obligation given defined benefit plans fair value plan assets reimbursement rights millions chf fair value reim fair value reim plan bursement plan bursement assets rights total assets rights total january expected return plan assets actuarial gains losses currency translation effects employer contributions employee contributions benefits paid funded plans past service cost divestment subsidiaries curtailments settlements december invested shares equity instruments bonds debentures debt instruments property assets total included within fair value plan assets none groups shares thousand shares fair value million swiss francs thousand groups nonvoting equity securities fair value million swiss francs thousand nonvoting equity securities total fair value million swiss francs roche finance report roche group notes roche group consolidated financial statements defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost employee contributions actuarial gains losses currency translation effects benefits paid funded plans benefits paid unfunded plans past service cost divestment subsidiaries curtailments settlements december funded plans unfunded plans actuarial assumptions actuarial assumptions unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters salary benefit levels interest rates return investments costs medical benefits group operates defined benefit plans many countries actuarial assumptions vary based upon local economic social conditions demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity mortality tables used major schemes germany heubeck tables g japan national census life table switzerland bvg united kingdom nonpensioners snal table rated years male years female future improvements medium cohort underpin united kingdom pensioners snal table rated years future improvements medium cohort underpin united states rp projected rates employee turnover disability early retirement based historical behaviour within group companies financial assumptions based market expectations period obligations settled ranges assumptions used actuarial valuations significant plans countries stable currencies interest rates shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates return plan assets expected rates salary increases immediate medical cost trend rate ultimate medical cost trend rate discount rates used calculate discounted present value defined benefit obligation determined reference market yields highquality corporate bonds government bonds countries deep market corporate bonds currency term bonds consistent obligation discounted interest cost included income statement calculated multiplying discount rate defined benefit obligation expected returns plan assets based market expectations expected returns assets funded plans duration related obligation takes account split plan assets equities bonds property investments calculation includes assumptions concerning expected dividend interest income realised unrealised gains plan assets taxes administration costs borne plan based longterm market expectations actual performance continually monitored corporate management due longterm nature obligations assumptions used matters returns investments may necessarily consistent recent historical patterns expected return plan assets included income statement calculated multiplying expected rate return fair value plan assets difference expected return actual return twelvemonth period actuarial gainloss recorded directly equity actual return plan assets gain million swiss francs gain million swiss francs expected rates salary increases used calculate defined benefit obligation current service cost included income statement based latest expectation historical behaviour within group companies medical cost trend rates used calculate defined benefit obligation current service cost included income statement postemployment medical plans take account benefits set plan terms expected future changes medical costs since groups major post employment medical plans us employees rates driven developments united states effect one percentage point increase decrease medical cost trend rate shown defined benefit plans sensitivity medical cost trend rate millions chf current service cost interest cost defined benefit obligation funding summary fiveyear summary funding status groups defined benefit plans shown table roche finance report roche group notes roche group consolidated financial statements defined benefit plans summary funding status millions chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation increase decrease funding status arising experience adjustments fair value plan assets defined benefit obligation increase decrease funding status arising changes actuarial assumptions fair value plan assets defined benefit obligation cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs includes estimated million swiss francs additional contributions benefits paid unfunded plans estimated approximately million swiss francs amounts recorded equity actuarial gains losses recognised statement comprehensive income losses million swiss francs losses million swiss francs pretax total amount december accumulated loss million swiss francs accumulated loss million swiss francs addition recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit asset recognition recorded directly equity adjustment decrease million swiss francs decrease million swiss francs employee stock options equity compensation plans group operates several equity compensation plans including separate plans genentech prior genentech transaction chugai effective january group adopted ifrs sharebased payment amongst matters standard requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading general administration costs include million swiss francs expenses accelerated vesting genentech equity compensation plans following genentech transaction see note expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans special stock awards roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche restricted stock unit plan chugai retirement stock acquisition rights roche performance share plan roche stock appreciation rights total equity compensation plans total operating expenses equitysettled cashsettled roche finance report roche group notes roche group consolidated financial statements cash inflow outflow equity compensation plans millions chf genentech equity compensation plans genentech stock option plan genentech employee stock purchase program total cash inflow genentech equity compensation plans equitysettled equity compensation plans roche option plan exercises chugai stock acquisition rights exercises roche connect costs total equitysettled equity compensation plans cash outflow transactions equity instruments total cash inflow outflow equitysettled equity compensation plans net transactions equity instruments cashsettled plans included part movements net working capital roche stock appreciation rights net cash outflow transactions equity instruments arises sales purchases non voting equity securities genussscheine derivative instruments thereon held groups potential conversion obligations may arise groups equitysettled equity compensation plans derivative instruments mainly consist call options exercisable time maturity see note addition cash flows upon completion genentech transaction remaining outstanding genentech employee stock options fully redeemed cash resulting cash outflow million swiss francs reported change ownership interest subsidiaries see note roche longterm group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan following integration genentech group also established restricted stock unit rsu plan first awards plan made september employees genentech ssars issued accordance roche ssar plan regulations january including amendments effective january addenda including roche ssar plans addendum united states september remuneration committee determines number nonvoting equity securities genussscheine available plan year regulations collectively provide million nonvoting equity securities genussscheine available issuance roche ssar plan tenyear period rsus issued accordance roche restricted stock unit plan regulations effective september million nonvoting equity securities genussscheine available issuance tenyear period details plans given relevant sections share option plans roche option plan awards plan give employees right purchase nonvoting equity securities genussscheine exercise price specified grant date options non tradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note introduction roche longterm number options granted roche option plan significantly reduced eligible employees receive roche stocksettled stock appreciation rights instead roche option plan movement number options outstanding number weighted average number weighted average options exercise price options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total genentech stock option plan genentech stock option plan adopted amended thereafter april genentechs shareholders approved equity incentive plan plans allowed granting various stock options incentive stock options stock purchase rights employees directors consultants genentech options granted nontradable equitysettled awards tenyear duration vested phased basis four years subject continued employment upon completion genentech transaction see note remaining outstanding options fully redeemed cash accounting purposes remaining fair value million swiss francs expensed options fully vested time roche finance report roche group notes roche group consolidated financial statements genentech stock option plan movement number options outstanding number weighted average number weighted average options exercise price options exercise price millions usd millions usd outstanding january granted forfeited exercised expired genentech transaction outstanding december exercisable chugai stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai right entitles holder purchase chugai shares specified exercise price rights nontradable equitysettled awards tenyear duration vest two years chugai stock acquisition rights movement number rights outstanding weighted average weighted average number exercise price number exercise price rights jpy rights jpy outstanding january granted forfeited exercised expired outstanding december exercisable chugai stock acquisition rights terms rights outstanding december rights outstanding rights exercisable weighted average weighted average weighted average number years remaining exercise price number exercise price year grant outstanding contractual life jpy exercisable jpy awards total issues share options issues share options including methodology used calculate fair value main inputs valuation models described issues share option plans roche chugai stock option plan acquisition rights number options granted underlying equity roche nonvoting chugai shares equity securities blocks currency swiss francs japanese yen vesting period progressively years years contractual life years years weighted average fair value options issued option pricing model used binomial binomial inputs option pricing model share price grant date exercise price expected volatility expected dividend yield early exercise factor na expected exit rate volatility roche chugai options determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour equity compensation plans special stock awards march december group issued special stock awards certain directors management employees selected discretion group awards consisted immediately vesting nonvoting equity securities genussscheine fair value awards calculated basis market value roche nonvoting equity securities date issue roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities genussscheine administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million programme operational since october year cost plan million swiss francs million swiss francs reported within relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allowed employees purchase genentechs common stock lower market value grant date purchase date total million shares genentech common stock purchased resulting cash inflow million swiss francs cost plan million swiss francs reported within relevant expenditure line function upon completion genentech transaction see note remaining outstanding awards fully redeemed cash accounting purposes remaining fair value million swiss francs expensed awards fully vested time roche finance report roche group notes roche group consolidated financial statements roche stocksettled stock appreciation rights introduction roche longterm group offers stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive non voting equity securities genussscheine reflecting value appreciation market price nonvoting equity securities grant date exercise date rights nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note roche ssars movement number rights outstanding number weighted average number weighted average rights exercise price rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average fair value rights granted calculated using binomial model inputs model consistent used roche option plan awards given previously except early exercise factor expected exit rate resulting weighted average fair value per right chf giving total fair value million swiss francs charged vesting period three years roche restricted stock unit plan first time september group issued restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities genussscheine vest threeyear period weighted average fair value awards granted chf calculated basis market value roche nonvoting equity securities date issue discounted take account awards would accrue dividends vesting period roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december exercisable chugai retirement stock acquisition rights first time chugai issued stock acquisition rights lieu retirement gratuities system directors abolished rights issued thirtyyear duration vest upon holders retirement director chugai right entitles holder purchase chugai shares exercise price japanese yen total fair value rights issued equivalent million swiss francs million swiss francs calculated using binomial model inputs consistent used chugai stock appreciation rights given previously roche performance share plan group offers future nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers programme established beginning currently operates annual threeyear cycles terms currently outstanding awards set table amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors nontradable equitysettled awards award result zero two nonvoting equity securities depending upon achievement performance targets roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions weighted average fair value awards granted calculated using monte carlo simulation input parameters model covariance matrix roche individual companies peer group based threeyear history riskfree rate valuation also takes account defined rank performance structure determines payout plan roche finance report roche group notes roche group consolidated financial statements roche stock appreciation rights employees certain north american subsidiaries group receive stock appreciation rights sars part compensation sars non tradable cashsettled awards may exercised vesting period one three years cash payment based upon amount market price groups american depositary receipts adrs point exercise exceeds strike price grant price issuance following implementation roche longterm see group plan award cashsettled sars awards made since roche stock appreciation rights millions chf liability december intrinsic value vested rights december roche stock appreciation rights terms rights outstanding december rights outstanding exercisable number outstanding exercisable weighted average year grant thousands expiry price usd feb total fair value december calculated using binomial model inputs model adr price december usd exercise prices given table inputs consistent used roche option plan awards given previously property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals lonza singapore acquisition business combinations transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january additions disposals marcadia acquisition business combinations transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence could result shortened useful lives impairment impairment charges million swiss francs million swiss francs reported part cost sales million swiss francs million swiss francs research development million swiss francs million swiss francs reported within general administration major part impairment reported general administration related discontinuation bulk drug production unit part site vacaville california see note roche finance report roche group notes roche group consolidated financial statements borrowing costs totalling million swiss francs using rate million swiss francs using rate capitalised property plant equipment leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value future payments minimum lease payments within one year one five years five years total future finance charges total future minimum lease p ayments undiscounted addition genentech leasing arrangements disclosed operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease payments noncancellable leases millions chf gross investment lease present value future minimum lease payments within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments december machinery equipment original cost million swiss francs million swiss francs net book value million swiss francs million swiss francs leased third parties contingent rent recognised income genentech leasing arrangements december genentech entered master lease agreement slough ssf llc subsequently acquired health care properties hcp development property adjacent genentechs south san francisco site development includes total eight buildings subject separate agreements contemplated master lease agreement hcp developer construct building shell building genentech finish interior building laboratory office space applicable construction first buildings completed point lease term buildings deemed begin construction final buildings completed lease term expires twelve years occupation final building genentech two fiveyear renewal options building option purchase various buildings different dates genentech also right first refusal respect building entire development hcp consider selling part development december total carrying value property plant equipment agreement million swiss francs million swiss francs carrying value genentech leasing obligations million swiss francs million swiss francs estimates total future minimum lease payments anticipated entire master lease agreement shown estimated total future minimum lease payments hcp leases millions chf total minimum principal ground lease interest lease payment within one year one five years five years total capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs roche finance report roche group notes roche group consolidated financial statements goodwill goodwill movements carrying value assets millions chf january lonza singapore acquisition marcadia acquisition business combinations impairment charge currency translation effects december allocated following cashgenerating units pharmaceuticals division roche pharmaceuticals chugai total pharmaceuticals division diagnostics division diabetes care professional diagnostics molecular diagnostics applied science tissue diagnostics trategic goodwill held divisional level allocated business areas total diagnostics division accumulated impairment losses goodwill goodwill arising investments associates classified part investments associates see note goodwill impairment testing pharmaceuticals division divisions subdivisions cashgenerating units used testing goodwill chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices chugai shares roche pharmaceuticals recoverable amount used impairment testing based value use cash flow projections used based recent business plans approved management assume significant changes organisation division include managements latest estimates sales volume pricing production operating costs reflect past experience projected five years cash flow projections used extend beyond managements recent business plans discount rate used based rate derived capital asset pricing model using data swiss capital markets including swiss federal government twentyyear bonds swiss market index weighted average tax rate used calculations management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections used based recent business plans approved management assume significant changes organisation division include managements latest estimates sales volume pricing production operating costs reflect past experience projected five years estimates tissue diagnostics business area projected ten years management believes reflects longterm nature business cash flow projections used extend beyond managements recent business plans discount rate used based rate derived capital asset pricing model using data swiss capital markets including swiss federal government twentyyear bonds swiss market index weighted average tax rate used calculations management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january lonza singapore acquisition business combinations additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group roche finance report roche group notes roche group consolidated financial statements product product intangibles marketing technology intangibles available intangibles intangibles use use use use total year ended december january marcadia acquisition business combinations additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group significant intangible assets december millions chf operating net book remaining segment value amortisation period product intangibles use tanox acquisition roche pharmaceuticals years chugai acquisition chugai years corangeboehringer mannheim acquisition diagnostics years igen acquisition diagnostics years ventana acquisition diagnostics years product intangibles available use intermune alliance roche pharmaceuticals na ventana acquisition diagnostics na classification amortisation impairment expenses millions chf amortisation impairment amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives impairment intangible assets impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment roche pharmaceuticals operating segment recorded impairment charge million swiss francs diagnostics operating segment recorded impairment charge million swiss francs amount recorded roche pharmaceuticals operating segment impairment charge million swiss francs recorded part operational excellence programme see note part programme division carried comprehensive portfolio review decided discontinue certain activities research early development addition certain product development activities discontinued transferred roche sites third parties result decisions intangible assets carrying value million swiss francs fully written apart operational excellence programme impairment charge million swiss francs also recorded pharmaceuticals division respect product intangibles available use follows primarily recent clinical data portfolio prioritisation decisions relating certain projects either alliance partners acquired business combinations assets concerned yet amortised fully written charges charge million swiss francs recorded resulting portfolio prioritisation decision project acquired part previous business combination asset concerned yet amortised written recoverable value million swiss francs based value use calculation using discount rate reversal previously recorded impairment loss million swiss francs recorded followed latest clinical data assessment project concerned diagnostics operating segment impairment charge million swiss francs recorded respect intangible assets use followed regular updating divisions business plans technology assessments second half assets concerned written recoverable amount million swiss francs based value use calculation using discount rate roche pharmaceuticals operating segment recorded impairment charge million swiss francs diagnostics operating segment recorded impairment charge million swiss francs roche pharmaceuticals operating segment impairment charge million swiss francs recorded related pharmaceuticals division reorganisation see note integration programme included prioritising projects within shared portfolio assets concerned fully written charges impairment charge million swiss francs also recorded respect product intangibles available use followed recent clinical data portfolio prioritisation decisions relating certain projects either alliance partners acquired business combinations assets concerned yet amortised written recoverable amount million swiss francs based value use calculation using discount rate addition impairment charge million swiss francs recorded relating intangible assets use followed regular updating divisions business plans technology assessments second half assets written recoverable amount million swiss francs based value use calculation using discount rate roche finance report roche group notes roche group consolidated financial statements diagnostics operating segment impairment charge million swiss francs recorded respect intangibles assets use followed regular updating divisions business plans technology assessments second half assets written recoverable amount million swiss francs based value use calculation using discount rate intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases december carrying value assets pharmaceuticals division million swiss francs amount approximately represents projects potential decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development process assets particularly risk impairment project question result commercialised product potential commitments alliance collaborations group party inlicensing similar arrangements alliance partners arrangements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration agreements groups current estimate future thirdparty commitments payments set table figures risk adjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total associates groups investments associates accounted using equity method goodwill arising investments associates classified part investments associates investments associates millions chf share net income carrying value total investments associates group significant investments associates material transactions group associates additional information associates given note financial longterm assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets longterm employee benefits total longterm assets financial longterm assets held strategic purposes classified noncurrent available forsale investments mainly equity investments primarily investments private biotechnology companies kept part groups strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value measured reliably carrying value equity investments held cost million swiss francs million swiss francs million swiss francs loans receivable comprise loans third parties term one year inventories inventories millions chf raw materials supplies work process intermediates finished goods less provision slowmoving obsolete inventory total inventories expenses relating inventories expensed cost sales totalled million swiss francs million swiss francs roche finance report roche group notes roche group consolidated financial statements accounts receivable accounts receivable millions chf trade accounts receivable notes receivable allowances doubtful accounts chargebacks allowances total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs billion swiss francs allowances doubtful accounts receivable movements recognised liability millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december expenses relating bad debts expensed marketing distribution totalled million swiss francs million swiss francs significant concentrations within trade receivables counterparty credit risk described note current assets current assets millions chf accrued interest income derivative financial instruments restricted cash total financial current assets prepaid expenses total nonfinancial current assets total current assets derivative financial instrument assets primarily related hedges nonus dollardenominated bonds notes issued finance genentech transaction decline compared december mainly due strengthening us dollar compared euro offset foreign currency transaction gains nonus dollardenominated bonds notes see note marketable securities marketable securities millions chf financial assets fairvaluethroughprofitorloss heldfortrading investments bonds debentures total financial assets fairvaluethroughprofitorloss heldtomaturity financial assets money market instruments time accounts three months total heldtomaturity financial assets availableforsale financial assets shares bonds debentures money market instruments time accounts three months investments total availableforsale financial assets total marketable securities marketable securities held fund management purposes classified current primarily denominated swiss francs investments held strategic purposes classified noncurrent see note heldfortrading investments held genentech sold shares consist primarily readily saleable equity securities bonds debentures carrying values contracted maturity debt securities shown roche finance report roche group notes roche group consolidated financial statements bonds debentures millions chf contracted maturity within one year one five years five years total bonds debentures money market instruments contracted mature within one year december cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents accounts payable accounts payable millions chf trade accounts payable taxes payable dividends payable accounts payable total accounts payable accrued current liabilities accrued liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities derivative financial instruments group uses derivative financial instruments part risk management activities discussed note derivative financial instruments carried fair value methods used determining fair value described note derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks managed using derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described roche finance report roche group notes roche group consolidated financial statements cash flow hedges group issued bonds notes finance genentech transaction see note bonds notes denominated euros sterling group entered crosscurrency swaps hedge foreign exchange interest rate risk cash flow hedges qualify hedge accounting december instruments designated qualify hedge accounting recorded assets fair value million swiss francs assets million swiss francs ineffective portion expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table decline expected cash flows due stronger swiss franc euro us dollar pound sterling expected cash flows qualifying cash flow hedges millions chf total months months months years years years years years year ended december cash inflows cash outflows total year ended december cash inflows cash outflows total undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity decline expected cash flows due stronger swiss franc euro us dollar pound sterling expected cash flows qualifying cash flow hedges impact profit loss millions chf total months months months years years years years years year ended december cash inflows cash outflows total year ended december cash inflows cash outflows total changes hedging reserve within equity shown note fair value hedges december group hedged fixedterm debt instruments interest rate swaps instruments designated qualified fair value hedges recorded balance sheet december assets fair value million swiss francs instruments expired july underlying bond redeemed loss million swiss francs recorded interest rate swaps loss million swiss francs fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments group equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure group entered forward contracts designated qualify fair value hedges december instruments recorded liabilities fair value million swiss francs assets million swiss francs loss million swiss francs recorded forward contracts loss million swiss francs result forward contracts offset changes fair value hedged equity investments group uses derivatives designated qualifying hedge relationship manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options roche finance report roche group notes roche group consolidated financial statements provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring employee provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised year unwinding discount business combinations currency translation effects december current portion noncurrent portion total provisions year ended december january additional provisions created unused amounts reversed utilised year unwinding discount business combinations acquired companies contingent consideration currency translation effects december current portion noncurrent portion total provisions expected outflow resources within one year one two years two three years three years total provisions legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies majority cash outflows matters expected occur within next one three years although dependent development various litigations significant provisions discounted time value money material environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict estimated timings cash outflows shown table significant provisions discounted time value money material restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain global basis shown table provisions discounted time value money material matters employee provisions mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash outflows reasonably estimated based past performance shown table significant provisions discounted time value money material provisions provisions mostly relate sales returns various provisions group companies fit categories timings cash outflows nature uncertain best estimates shown table provisions discounted time value money material matters contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note pharmaceuticals legal cases accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions united states elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders december hlr defending approximately actions brought various federal state courts throughout united states personal injuries allegedly resulting use accutane actions allege ibd result accutane use june hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product united states roche finance report roche group notes roche group consolidated financial statements actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation united states district court middle district florida tampa division july district court granted summary judgment favour hlr lead federal ibd cases plaintiffs appealed august rulings affirmed united states court appeals eleventh circuit october district court granted summary judgment favour hlr next five federal ibd cases plaintiffs appealed november may rulings affirmed united states court appeals eleventh circuit several recently filed matters remain pending actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county december juries superior court ruled favour plaintiff six cases assessing total compensatory damages totalling million us dollars first verdict reversed appeal retrial resulted verdict favour plaintiff assessing total compensatory damages million us dollars hlr currently process posttrial briefing second verdict reversed appeal retrial scheduled may additional plaintiffs may added trial hlr appealed third verdict superior court new jersey appellate division involved three plaintiffs next trial involving three plaintiffs scheduled february october jury circuit court escambia county florida returned verdict favour plaintiff assessing total compensatory damages million us dollars subsequently reduced million us dollars court company october district court appeal state florida reversed entered judgment hlr supreme court florida declined review plaintiffs appeal additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims boniva hlr various roche affiliates named defendants numerous legal actions united states relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused one following conditions osteonecrosis jaw onj atypical femoral fractures severe bone pain december hlr defending approximately actions brought federal state courts states new jersey new york california personal injuries allegedly resulting use boniva boniva cases early discovery stages litigation trial dates set individual trial results depend variety factors including many unique particular case hlr named roche affiliates intend vigorously defend matters outcome matters determined time cabilly patent may centocor inc filed patent lawsuit genentech city hope national medical center city hope us district court central district california lawsuit related us patent cabilly patent coowned genentech city hope cabilly patent expires relates methods used genentech others make certain antibodies antibody fragments well cells dna used methods genentech licensed cabilly patent companies derives significant royalties licences lawsuit sought declaratory judgment patent invalidity unenforceability regard cabilly patent patent noninfringement regard certain centocors products august genentech centocor entered settlement agreement resolving lawsuit certain additional patent issues agreement effective april regard royalties centocor agreed pay licenses cabilly patent matter finally resolved october glaxo group limited smithkline beecham corporation glaxosmithkline llc collectively gsk filed patent lawsuit genentech city hope us district court southern district florida lawsuit relates cabilly patent seeks declaratory judgment patent invalidity unenforceability regard cabilly patent patent noninfringement regard certain gsk product december genentech filed motion dismiss alternative transfer central district california gsk dismissed florida lawsuit entirety february filed related action day northern district california genentech filed motion transfer central district california answer counterclaim gsk march april genentechs motion transfer granted october court entered order related claim construction matters including setting markman hearing date february outcome matter determined time litigation june mr ubaldo bao martinez filed lawsuit porrio town council genentech espaa sl contentious administrative court number one pontevedra spain lawsuit challenged town councils decision grant licenses genentech espaa sl construction operation warehouse biopharmaceutical manufacturing facility porrio spain january administrative court ruled favour mr bao one claims lawsuit ordered closing demolition facility subject certain legal proceedings february genentech espaa sl town council filed appeals administrative court decision high court galicia spain march genentech received notice prevailed mr bao appeal decision revokes january ruling entirety october genentech received subpoena united states department justice requesting documents related promotion rituxan genentech cooperated governments associated investigation previously investigation civil criminal nature genentech informed august criminal prosecutor handled matter government declined prosecute genentech criminally connection investigation civil matter still ongoing counsel genentech continued discussions government representatives status investigation genentechs views matter including potential resolution october government notified genentech decided make civil claim genentech governments investigation initiated complaint filed seal us district court eastern district pennsylvania individual plaintiff complaint unsealed december currently basis civil litigation plaintiff roche holdings inc genentech discovery matter ongoing group intends vigorously defend outcome civil litigation determined time hlr roche laboratories inc rli genentech along approximately brand generic pharmaceutical companies named defendants several legal actions united states relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending six actions filed following states alabama mississippi new jersey kansas oklahoma louisiana genentech defending one action filed state kansas discovery currently pending cases hlr rli genentech intend vigorously defend matters outcome matters determined time roche finance report roche group notes roche group consolidated financial statements hlr along various branded pharmaceutical companies named defendant several legal actions united states brought retail pharmacies relating discounting practices brand name prescription drugs bnpd bnpd litigations plaintiffs allege denied discounts certain prescription drugs offered mail order managed care entities denial claimed violation robinsonpatman act rpa rpa federal law prohibits unlawful price discrimination addition plaintiffs alleged defendants conspired refusal offer certain discounts conspiracy claims defendants previously settled rpa claims remaining litigated december hlr defending approximately bnpd actions brought approximately retail pharmacies various federal state courts throughout united states discovery currently pending cases hlr currently scheduled trial bnpd matters hlr intends vigorously defend outcome matters determined time november novartis vaccines diagnostics inc former chiron affiliate novartis filed lawsuit trimeris inc four roche group companies hoffmannla roche inc f hoffmannla roche ltd roche laboratories inc roche colorado corp us district court eastern district texas complaint sought injunction damages manufacture sale roches antiaids drug fuzeon united states novartis alleged activities infringed claims us patent september matter settled roche trimeris taking royaltybearing license novartis patent may june august september genentech named defendant along intermune inc former chief executive officer w scott harkonen four separate classaction complaints filed us district court northern district california behalf plaintiffs allegedly paid part purchase price product licensed genentech connectics corporation subsequently assigned intermune genentech responded complaints motion dismiss matters granted april plaintiffs filed amended complaints including state law claims may genentech responded complaints another motion dismiss heard september court granted genentechs motion dismiss respect claims leave plaintiffs replead specific claims california unfair competition law plaintiffs filed amended class action complaint december naming genentech defendant claims unfair competition law false advertising law consumer remedies law consumer protection law unjust enrichment genentech sought dismissal amended complaint september court entered order granting genentechs motion dismiss claims prejudice plaintiffs filed appeal district courts ruling united states court appeals ninth circuit briefing appeal ongoing outcome matter determined time october genentech biogen idec inc filed complaint sanofiaventis deutschland gmbh sanofi sanofiaventis us llc sanofiaventis us inc northern district california seeking declaratory judgement certain genentech products including rituxan infringe sanofis us patents declaratory judgement patents invalid also october sanofi filed suit genentech biogen idec eastern district texas lufkin division claiming rituxan least eight genentech products infringe patents sanofi brought claims preliminary permanent injunctions compensatory exemplary damages relief genentech challenged venue texas case opinion federal circuit court appeals texas california cases consolidated northern district california district court issued claim construction order june sanofi filed motion reconsideration denied genentech biogen idec filed motions summary judgment sanofi opposed ruling motions issued discovery consolidated matters ongoing addition october hoechst gmbh filed icc international court arbitration paris request arbitration genentech relating terminated agreement hoechsts predecessors genentech pertained patents related patents outside united states hoechst seeking payments royalties sales genentech products damages breach contract relief icc arbitration hearing held august september posthearing briefs filed ruling expected first half outcome matters determined time may genentech filed patent lawsuit university pennsylvania us district court northern district california lawsuit relates united states patent seeks declaratory judgment patent noninfringement invalidity regard patent july university counterclaimed genentech infringement patent seeking unspecified damages based sales herceptin genentech filed answer august case management conference held august markman hearing currently scheduled march discovery matter ongoing outcome matter determined time august pdl biopharma pdl filed complaint genentech nevada state court seeking judicial declaration concerning genentechs obligation pay royalties certain exus sales herceptin avastin xolair lucentis agreement parties september pdl filed first amended complaint asserting additional claims genentech including breach contract breach implied covenant good faith fair dealing pdl also asserted new claims roche novartis intentional interference contractual relations addition declaratory relief pdl seeking monetary damages including liquidated punitive damages november genentech roche filed motion dismiss failure state claim roche filed additional motion dismiss lack personal jurisdiction outcome matter determined time september gsk genentech filed patent lawsuits one another case gsk also roche holding ltd us district courts district delaware northern district california respectively lawsuits concern gsks us patent nos gsk asserted claims genentech roche alleging infringement patents certain therapeutic antibody products although complaint specifically refers herceptin lawsuit genentech seeking judicial declaration noninfringement certain genentech products delaware action november genentech filed motion dismiss failure state claim motion transfer case california roche filed motion dismiss lack personal jurisdiction joining genentechs motion event personal jurisdiction motion denied motions currently pending california action december court entered order staying california action pending resolution delaware court genentechs motion transfer outcome matters determined time roche finance report roche group notes roche group consolidated financial statements noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt gains losses redemption repurchase bonds notes net amortisation debt discount gains losses financial liabilities fairvaluethroughprofitorloss net foreign currency transaction gains losses net currency translation effects december consisting bonds notes commercial paper amounts due banks financial institutions genentech leasing obligations finance lease obligations borrowings total debt reported longterm debt shortterm debt total debt fair value bonds notes billion swiss francs billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs billion swiss francs calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollardenominated notes floating rate months libor notes due february principal billion us dollars na notes due february principal million us dollars na us dollardenominated notes fixed rate notes due march principal billion us dollars na notes due march principal billion us dollars na notes due march principal billion us dollars na notes due march principal billion us dollars na european medium term note programme floating rate months euribor notes due march principal billion euros european medium term note programme fixed rate notes due march principal billion euros notes due march principal billion pounds sterling notes due march principal billion euros notes due march principal billion euros notes due august principal million pounds sterling na swiss franc bonds bonds due march principal amount billion swiss francs bonds due march principal amount billion swiss francs na us dollar bonds chameleon due july principal million us dollars na genentech senior notes senior notes due july principal million us dollars na senior notes due july principal billion us dollars na senior notes due july principal million us dollars na total principal amount billion us dollars notes billion us dollars redeemed march following groups resolution early redeem notes see roche finance report roche group notes roche group consolidated financial statements bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds sterling notes total unamortised discount fair value option group applied fair value option three outstanding debt instruments group applying fair value hedge accounting past debt instruments european medium term note programme euro bonds chameleon us dollar bonds rodeo swiss franc bonds instruments fully redeemed due dates fair value option treatment based elimination accounting mismatch recognised hedging swaps reported fair value hedged bonds reported amortised cost issuance new bonds notes new bonds notes issued issuance new bonds notes group financed genentech transaction see note combination groups funds debt securities commercial paper group raised net proceeds approximately billion swiss francs series debt offerings described newly issued debt senior unsecured guaranteed roche holding ltd us dollardenominated notes february group completed offering us dollardenominated notes qualified institutional buyers united states rule persons us persons outside united states regulation us securities act group received approximately billion us dollars aggregate net proceeds issuance sale fixed floating rate notes march group completed offering us dollardenominated notes rule us securities act roche received approximately billion us dollars aggregate net proceeds issuance sale fixed rate notes terms proceeds notes follows issuance us dollardenominated notes principal amount net proceeds usd millions chf millions floating rate notes due floating rate notes due fixed rate notes due fixed rate notes due fixed rate notes due fixed rate notes due fixed rate notes due total european medium term note programme march group issued euro sterling denominated fixed floating rate notes terms proceeds notes follows issuance european medium term notes principal amount net proceeds eur millions gbp millions chf millions floating rate eur notes due fixed rate eur notes due fixed rate gbp notes due fixed rate eur notes due fixed rate eur notes due total subsequent debt issuances proceeds notes swapped us dollars result financial statements notes economic characteristics equivalent us dollardenominated notes swiss francdenominated bonds notes march group completed offering swiss francdenominated fixedrate bonds terms proceeds bonds follows issuance swiss francdenominated bonds principal amount net proceeds chf millions chf millions fixed rate bonds due fixed rate bonds due fixed rate bonds due total subsequent debt issuances proceeds swiss francdenominated bonds swapped us dollars result financial statements bonds economic characteristics equivalent us dollardenominated bonds cash inflows issuance bonds notes millions chf us dollardenominated notes european medium term note programme euro sterlingdenominated notes swiss francdenominated notes total cash inflows issuance bonds notes redemption repurchase bonds notes redemption us dollardenominated notes due date february group redeemed notes principal billion us dollars original issue amount plus accrued original issue discount oid effective interest rate notes months libor plus cash outflow million swiss francs gain loss recorded redemption redemption european medium term note programme notes due date march group redeemed notes principal billion euros original issue amount plus accrued original issue discount oid effective interest rate notes months euribor plus plus including hedging cash outflow million swiss francs gain loss recorded redemption roche finance report roche group notes roche group consolidated financial statements redemption genentech senior notes due date july group redeemed notes principal million us dollars original issue amount plus accrued original issue discount oid effective interest rate bonds cash outflow million swiss francs gain loss recorded redemption early redemption us dollardenominated notes june group resolved exercise option call redemption us dollardenominated fixed rate notes due march principal billion us dollars group redeemed notes september amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal effective interest rate notes redemption cash outflow million swiss francs plus accrued interest loss redemption million swiss francs recorded within financing costs see note december group resolved exercise option call redemption portion us dollardenominated fixed rate notes due march group redeem billion us dollars total principal amount billion us dollars notes march amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal us treasury rate determined independent investment banker third business day preceding redemption cash outflow approximately million us dollars plus accrued interest expected redemption group revised carrying value notes take account changes amounts timings estimated cash flows revised carrying value notes december million us dollars million swiss francs increase carrying value million us dollars million swiss francs recorded within financing costs see note loss redemption effective interest rate notes redemption repurchase bonds notes redemption chameleon us dollar bonds group redeemed bonds remaining outstanding principal value million us dollars due date july original issue amount plus accrued original issue discount oid effective interest rate bonds cash outflow million swiss francs gain loss recorded income statement upon redemption redemption repurchase us dollardenominated notes group redeemed notes principal value million us dollars due date september original issue amount plus accrued original issue discount oid effective interest rate bonds cash outflow million swiss francs gain loss recorded income statement upon redemption addition group repurchased floating rate notes principal value million us dollars original due date february various dates open market purchases effective interest rate bonds months libor plus cash outflow million swiss francs loss million swiss francs recorded income statement upon repurchase redemption swiss francdenominated notes group redeemed notes principal value million swiss francs due date september original issue amount plus accrued original issue discount oid effective interest rate bonds including associated hedging instruments cash outflow million swiss francs gain loss recorded income statement upon redemption cash outflows redemption repurchase bonds notes millions chf us dollardenominated notes european medium term note programme eurodenominated notes genentech senior notes chameleon us dollar bonds swiss francdenominated notes total cash outflows redemption repurchase bonds notes collateral arrangements collateral agreements entered derivative counterparties currency swaps mitigate counterparty risk fair value derivative instruments moved due mainly stronger us dollar compared euro total billion swiss francs cash collateral delivered group billion swiss francs delivered group collateral delivered recorded decrease cash corresponding decrease accrued liabilities carrying value accrued liabilities respect agreements billion swiss francs december accrued liabilities billion swiss francs realised loss derivatives billion swiss francs realised gain billion swiss francs relates mainly hedges nonus dollar denominated bonds notes commercial paper genentech commercial paper program october genentech established commercial paper program could issue billion us dollars unsecured commercial paper notes december unsecured commercial paper notes principal amount million us dollars outstanding first six months group fully redeemed notes maturity principal value genentech terminated commercial paper program may amounts outstanding december roche holdings inc commercial paper program march roche holdings inc established commercial paper program issue billion us dollars unsecured commercial paper notes guaranteed roche holding ltd committed credit lines billion euros million us dollars available backstop lines maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount million us dollars average interest rate outstanding amounts due various dates january movements commercial paper obligations millions chf january net cash proceeds payments genentech commercial paper program roche holdings inc commercial paper program total net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies notably taiwanese dollars average interest rate average interest rate balance primarily denominated chinese renminbi repayment dates three years million swiss francs million swiss francs due within one year roche finance report roche group notes roche group consolidated financial statements equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments valuation gains losses taken equity transferred income statement sale impairment income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement transferred initial carrying value hedged items income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment noncontrolling interests defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends paid equity compensation plans net transactions equity instruments chugai share repurchases changes ownership interests subsidiaries genentech memory changes noncontrolling interests december amounts transferred income statement losses million swiss francs reported royalties operating income gains million swiss francs financial income changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments valuation gains losses taken equity transferred income statement sale impairment income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign perations exchange differences noncontrolling interests defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends paid equity compensation plans net transactions equity instruments changes noncontrolling interests movements december amounts transferred income statement gains million swiss francs reported royalties operating income losses million swiss francs financial income group completed purchase noncontrolling interests genentech effective march described note based revised international accounting standard consolidated separate financial statements ias adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacts groups net equity effect groups business dividend policy roche finance report roche group notes roche group consolidated financial statements share capital december authorised issued share capital roche holding ltd groups parent company consisted shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares described note based information supplied group novartis ltd basel affiliates participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend swiss francs per share nonvoting equity securities swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board directors proposed dividends business year swiss francs per share nonvoting equity security approved would result total distribution shareholders million swiss francs subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities december december millions millions nonvoting equity securities derivative instruments total equity instruments recorded within equity original purchase cost details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number nonvoting equity securities strike price market value millions maturity chf chf billions nonvoting equity securities derivative instruments feb sep total nonvoting equity securities derivative instruments held groups potential conversion obligations may arise roche option plan roche stocksettled stock appreciation rights roche restricted stock unit plan see note mainly consist call options exercisable time maturity group holds none shares reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares non voting equity securities reduced weighted average number nonvoting equity securities held group period basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf roche finance report roche group notes roche group consolidated financial statements diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise employee stock option plans exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested chugai prior genentech transaction genentech employee stock options would dilutive effect net income chugai genentech positive diluted earnings per share nonvoting equity security reflects potential impacts dilutive effects earnings per share figures diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding genentech chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement genentech chugai noncontrolling interests total net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income net tax total comprehensive income memory acquisition dividends paid noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity instruments chugai share repurchases changes ownership interests subsidiaries genentech memory changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests noncontrolling interests made equity contributions million swiss francs zero roche finance report roche group notes roche group consolidated financial statements statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense associates financial income financing costs income taxes operating profit depreciation property plant equipment amortisation intangible assets impairment intangible assets impairment property plant equipment operating expenses defined benefit postemployment plans operating expenses equitysettled equity compensation plans net income expense provisions bad debt expense inventory writedowns adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity significant noncash transactions significant noncash transactions total purchase consideration million us dollars lonza singapore million us dollars million swiss francs noncash settlement loans previously made genentech lonza see note information risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management specifically described detail financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai roche finance report roche group notes roche group consolidated financial statements carrying value fair value financial assets millions chf carrying value asset class available fvtplaheld held loans line items notes forsale trading maturity receivables total fair value year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total fairvaluethroughprofitorloss following implementation amendments ifrs financial instruments disclosures published march group established fair value hierarchy reflects significance inputs used making fair value measurements fair value hierarchy includes following three levels level quoted prices active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial assets liabilities december millions chf level level level total financial assets recognised fair value marketable securities money market instruments time accounts months bonds debentures shares derivative financial instruments availableforsale investments total financial liabilities recognised fair value derivative financial instruments total fair value hierarchy financial assets liabilities december millions chf level level level total financial assets recognised fair value marketable securities money market instruments time accounts months bonds debentures shares derivative financial instruments availableforsale investments total financial liabilities recognised fair value derivative financial instruments total availableforsale investments exclude equity securities held cost million swiss francs million swiss francs carried fair value see note december level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments unquoted shares december level financial assets consist auctionrate student loan securities securities valued based brokerprovided valuation models approximate fair value sold par value significant transfers level level vice versa roche finance report roche group notes roche group consolidated financial statements changes fair value level financial assets millions chf january impairment charges valuation gains losses taken equity gains losses recognised income statement sales currency translation difference december credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets trade receivables subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective management trade receivables sustain growth profitability group optimising asset utilisation whilst maintaining risks acceptable level except noted significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties additionally group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held loans receivables none december groups combined trade accounts receivable balance three us national wholesale distributors amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss francs representing groups consolidated trade accounts receivable billion swiss francs representing nature geographical location trade receivables overdue counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total cash marketable securities subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions group received zero coupon greek government bonds settlement overdue receivables allocated bbbrange rating analysis cash fixed income marketable securities market values mchf total mchf total aaarange aarange arange bbbrange bbbrange total derivatives group signs netting collateral agreements isda international swaps derivatives association master agreement respective counterparties order mitigate counterparty risk derivative positions group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued groups us affiliate roche holdings inc currencies us dollar total exposure hedged issuance bonds notes approximately billion swiss francs see note fair value derivative instruments moved due weaker us dollar net cash collateral billion swiss francs delivered group december group returned billion swiss francs due strengthening us dollar euro pound sterling overdue assets financial assets past due impaired total billion swiss francs billion swiss francs analysis overdue impaired financial assets class millions chf total amount overdue month months months months year year ended december loans receivables year ended december loans receivables since beginning increasing financial difficulties certain southern european countries particularly greece group leading supplier greek healthcare sector trade receivables greek public customers second half group accepted offer made greek government settle large parts overdue trade receivables zero coupon government bonds redeemable first government bonds received late december group expects receive remaining government bonds first half group carefully monitoring situation assessing options manage counterparty exposures december financial assets whose terms renegotiated none roche finance report roche group notes roche group consolidated financial statements liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time group liquidity reported senior management monthly basis roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements addition group unused committed credit lines various financial institutions totalling billion swiss francs billion swiss francs decline undiscounted financial liabilities shown table mainly due debt repayments interest paid well currency translation effects stronger swiss franc euro us dollar pound sterling contractual maturity analysis financial liabilities millions chf total months months months years years years years years year ended december total debt trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities year ended december total debt trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities total debt table shows undiscounted cash flows whereas carrying value consolidated balance sheet reflects discounted cash flows market risk market risk arises changing market prices groups financial assets financial liabilities market risk may affect group financial result value group equity group uses valueatrisk var measure impact market risk financial instruments roche defined var limits manage market risk var data reported monthly basis indicate value range within given financial instrument fluctuate preset probability result movements market prices var statistical measure implicitly assumes value changes recent past indicative value changes future var figures represent actual expected losses possible worstcase losses stated period var figures calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate longer holding periods increase probability higher value changes lead increased var figures actual future gains losses associated treasury activities may differ materially var analyses performed due inherent limitations associated predicting timing amount changes interest rates foreign currency exchanges rates equity investment prices particularly periods high market volatilities furthermore var numbers include effect changes credit spreads market risk financial instruments millions chf december december var foreign exchange component var interest rate component var price component diversification var total market risk december total var financial assets liabilities million swiss francs december million swiss francs interest rate var decreased million swiss francs reflecting ageing debt repayment debt higher duration fixed income assets held issued debt held amortised cost interest rate var sole metric economic fair value changes impact carrying value profit loss group foreign exchange var remained stable price risk arises mainly movements prices equity securities declined equity securities holdings reduced december group held equity securities market value billion swiss francs december billion swiss francs includes holdings biotechnology companies acquired context licensing transactions scientific collaborations foreign exchange risk group operates across world exposed movements foreign currencies affecting group financial result value groups equity foreign exchange risk arises amount local currency paid received transactions denominated foreign currencies may vary due changes exchange rates transaction exposures foreign currency denominated financial statements groups foreign subsidiaries may vary upon consolidation swiss francdenominated group financial statements translation exposures objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group currently hedge translation exposures using financial instruments group monitors transaction exposures daily basis net foreign exchange result corresponding var parameters reported monthly basis group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates roche finance report roche group notes roche group consolidated financial statements interest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity changes interest rates may cause variations interest income expense addition may affect market value certain financial assets liabilities hedging instruments primary objective groups interest rate management protect net interest result interest rate exposures corresponding var parameters reported monthly basis group uses forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures price risk price risk arises mainly movements prices equity securities december group held equity securities market value billion swiss francs billion swiss francs amount includes holdings biotechnology companies acquired context licensing transactions scientific collaborations due nature business biotechnology companies exposed greater equity volatilities general stock market fluctuations group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments equity price risk reported var figure monthly basis senior management impairment financial assets impairments loans receivables mainly due increase expected nonrecoverability trade receivables see also note impairment losses asset classes millions chf loans receivables availableforsale financial assets shares investments debt securities total impairment losses capital group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events group completed purchase noncontrolling interests genentech effective march described note based revised international accounting standard consolidated separate financial statements ias adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacts groups net equity effect groups business dividend policy capital monitored basis capitalisation calculated debt plus equity including noncontrolling interests reported senior management part groups regular internal management reporting groups capitalisation shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined local management related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares based information supplied shareholder group pooled voting rights comprising december ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms maja oeri mr jrg duschmal mr lukas duschmal group holds shares preceding year represents issued shares figure include shares without pooled voting rights held outside group individual members group mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling swiss francs swiss francs dr oeri received remuneration totalling swiss francs swiss francs transactions group individual members shareholder group subsidiaries associates listing major group subsidiaries associates included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates key management personnel members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees total remuneration board directors excluding chairman totalled million swiss francs million swiss francs roche finance report roche group notes roche group consolidated financial statements chairman board directors members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members corporate executive committee mr oday dr soriot included table full calendar year joined cec remuneration chairman board directors members corporate executive committee millions chf salaries including bonuses expenses special stock awards social security costs pensions postemployment benefits equity compensation plans employee benefits total purposes remuneration disclosures values equity compensation plans including special stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included financial statements roche holding ltd basel pages disclosures values equity compensation plans including special stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration chairman board directors members corporate executive committee ifrs basis see table deduct special stock awards ifrs basis equity compensation plans ifrs basis add back special stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration chairman board directors members corporate executive committee swiss legal basis chairman board directors members corporate executive committee special stock awards chairman board directors members corporate executive committee granted special stock awards lieu part cashsettled bonus financial year awards roche longterm members corporate executive committee granted stocksettled stock appreciation rights ssars roche option plan rop restricted stock unit rsu awards ssars rop rsu awards roche connect contributions paid group respect chairman board directors members corporate executive committee totalled million swiss francs million swiss francs roche performance share plan members corporate executive committee targeted awards cycle awards cycle award result zero two nonvoting equity securities depending upon achievement performance targets transactions former members corporate executive committee pensions tax consulting services totalling million swiss francs paid group four former corporate executive committee members million swiss francs two former members postemployment benefit plans transactions group various postemployment defined benefit plans employees group described note subsidiaries associates divestments subsidiaries effective august group sold wholly owned subsidiary lakeside de mxico sa de cv lakeside million swiss francs cash gain loss divestment subsidiaries millions chf consideration net assets disposed property plant equipment cash net assets accumulated currency translation adjustments gain loss divestment total gain loss divestment reported within general administration expenses part segment result roche pharmaceuticals operating segment net cash inflow divestments million swiss francs roche finance report roche group notes roche group consolidated financial statements listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy nonlisted companies share capital equity interest country company city millions argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china holding shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostics hvidovre dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eek finland roche diagnostics oy espoo eur roche oy espoo eur france roche diagnostics france sas meylan eur roche sas neuillysurseine eur ventana medical systems sa illkirch eur share capital equity interest country company city millions germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche innovatis ag bielefeld eur roche kulmbach gmbh kulmbach eur roche pharma ag grenzachwyhlen eur swisslab gmbh berlin eur greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche products india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd petach tikva ils italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius lit malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd kuala lumpur myr mexico productos roche sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panam sa panama city pab productos roche interamericana sa panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc makati php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche products proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabetes care ag burgdorf chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics ag rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche glycart ag schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev usd united kingdom piramed limited berkshire gbp roche diagnostics ltd lewes gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd alios biopharma inc south san francisco usd bioveris corporation gaithersburg usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd idaho technology inc salt lake city usd igen international inc wilmington usd marcadia biotech inc wilmington usd memory pharmaceuticals corp montvale usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostics corporation indianapolis usd roche diagnostics operations inc indianapolis usd roche holdings inc wilmington usd roche insulin delivery systems inc fishers usd roche laboratories inc nutley usd roche madison inc madison usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc palo alto usd spring bioscience corp fremont usd therapeutic human polyclonals inc palo alto usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef share capital less local currency units roche group report roche management internal control financial reporting roche finance report report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages franz b humer erich hunziker chairman board directors chief financial officer deputy head corporate executive committee basel january roche finance report roche group report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying consolidated financial statements roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flows statement changes equity notes pages year ended december board directors responsibility board directors responsible preparation fair presentation consolidated financial statements accordance international financial reporting standards ifrs requirements swiss law responsibility includes designing implementing maintaining internal control system relevant preparation fair presentation consolidated financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion consolidated financial statements based audit conducted audit accordance swiss law swiss auditing standards international standards auditing standards require plan perform audit obtain reasonable assurance whether consolidated financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures consolidated financial statements procedures selected depend auditors judgment including assessment risks material misstatement consolidated financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation fair presentation consolidated financial statements order design audit procedures appropriate circumstances audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation consolidated financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statements year ended december give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag john morris franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche finance report roche group report independent auditor internal control financial reporting report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examined roche groups system internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides reasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag john morris franois rouiller basel january roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting dividend proposed board directors standards applied retrospectively statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting dividend proposed board directors standards applied retrospectively roche finance report roche group multiyear overview supplementary information sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information based members eu december comparative information restated include new eu members whole fiveyear period roche finance report roche group multiyear overview supplementary information core results eps information groups basic diluted earnings per share information given note consolidated financial statements pages group expanded presentation core results previously core eps shown full income statement group operating results divisions shown ifrs core basis allows transparent assessment actual results underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring costs see note excluded amortisation impairment intangible assets see note excluded acquisition accounting onetime impacts alliance arrangements business combinations see financial review excluded discontinued operations currently none would excluded legal environment expenses see financial review excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note material onetime treasury items major debt restructurings settlement pension plans currently none would excluded global issues outside healthcare sector beyond groups control currently none would excluded core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables avoid doublecounting amounts shown global restructuring exclude items operational excellence programme included adjustment columns impairment intangible assets totalling million swiss francs see note additional commentary adjustment items given financial review core results reconciliation millions chf alliances normali global intangibles business legal sation restruc amorti intangibles combi environ ecp tax ifrs turing sation impairment nations mental benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf alliances normali global intangibles business legal sation restruc amorti intangibles combi environ ecp tax ifrs turing sation impairment nations mental benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche finance report roche group multiyear overview supplementary information divisional core results reconciliation millions chf alliances global intangibles business legal restruc amorti intangibles combi environ ifrs turing sation impairment nations mental core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf alliances global intangibles business legal restruc amorti intangibles combi environ ifrs turing sation impairment nations mental core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit core eps core net income chf millions core net income attributable roche shareholders increase noncontrolling interests share core net income assuming outstanding genentech chugai stock options exercised net income used calculate diluted earnings per share per share information millions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed exercise equity compensation plans dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share core earnings per share diluted chf roche finance report roche group multiyear overview supplementary information supplementary operating free cash flow information divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment intangible assets total adjustments add back e xpenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct net cash flow equity compensation plans utilisation provisions proceeds disposals total operating profit cash adjustments ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales roche group roche securities roche finance report roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased four roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january roche finance report roche group roche securities number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number nonvoting equity securities genussscheine held yearend total issue data per share nonvoting equity security chf earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche holding ltd basel financial statements roche finance report roche holding ltd basel financial statements income statement millions chf year ended december income income participations interest income loans group companies interest investment income guarantee fee income group companies income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year roche finance report roche holding ltd basel financial statements balance sheet millions chf december december noncurrent assets participations longterm loans longterm loans group companies total noncurrent assets current assets shortterm loans group companies accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value roche holding ltd basel notes financial statements roche finance report notes financial statements summary significant accounting policies basis preparation financial statements financial statements roche holding ltd basel prepared accordance provisions swiss law participations major participations company listed note roche group consolidated financial statements valuation methods translation foreign currencies marketable securities reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred taxes tax charge includes corporate income capital taxes equity share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates roche finance report roche holding ltd basel notes financial statements movement recognised amounts millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december net income dividends paid december contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december billion swiss francs billion swiss francs primarily relate additional bonds notes issued group companies finance genentech transaction guaranteed company described note roche group consolidated financial statements pages significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company shares shareholder group pooled voting rights comprising december ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms maja oeri mr jrg duschmal mr lukas duschmala shares participation novartis ltd basel including affiliates thereofb information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis ltd basel risk management detailed disclosures regarding risk management required swiss law included roche group consolidated financial statements pages board executive remuneration board directors members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration members board directors thousands chf b gehrig hoffmann p baschera ji bell p brabeckletmathe wm burns ljr de vink w frey da julius ar levinson oeri w ruttenstorfer h teltschik b weder di mauro total remuneration board directors remuneration dr levinson includes payments consulting work board membership genentech totalling thousand swiss francs chairman board directors dr franz b humer received remuneration shown table remuneration chairman board directors thousands chf annual salary including bonuses expenses special stock awards pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total roche finance report roche holding ltd basel notes financial statements corporate executive committee members corporate executive committee cec roche holding ltd receive remuneration indirect benefits participate certain equity compensation plans shown table groups ceo dr severin schwan member corporate executive committee highest total remuneration remuneration also disclosed new members corporate executive committee mr oday dr soriot included full calendar year joined cec remuneration members corporate executive committee thousands chf total cec schwan total cec schwan annual salary including bonuses expenses special stock awards pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total special stock awards chairman board directors members corporate executive committee granted total special stock awards chairman board directors received awards members cec received total awards awards granted dr schwan fair value awards employee calculated based fair value nonvoting equity securities genussscheine grant date chf chf discounted take account period blocked years years awards employer contribution social security schemes pension plans group pays social insurance contributions respect remuneration pays contributions pension post employment benefit plans chairman board directors members corporate executive committee equity compensation plans chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions awards disclosed note consolidated financial statements fair values used consolidated financial statements represent cost company grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions purposes remuneration disclosures values calculated based fair value employee receives taking account preliminary assessment completed performance conditions chairman board directors members corporate executive committee eligible participate roche connect programme enables employees make regular deductions salaries purchase nonvoting equity securities group contributes programme allows employees purchase nonvoting equity securities discount usually members corporate executive committee granted stocksettled stock appreciation rights ssars individual awards relating shown table fair value awards employee swiss francs calculated using blackscholes formula assuming holding maturity deducting average twoyear vesting period members corporate executive committee members senior management participate roche performance share plan psp group three overlapping threeyear psps target awards threeyear cycle defined beginning cycle awards considered form part employees remuneration three equal annual amounts threeyear cycle award result zero two nonvoting equity securities genussscheine depending upon achievement performance targets discretion board directors individual awards relating shown table number awards calculated follows psp end cycle performance targets achieved accordingly participants received none originally targeted nonvoting equity securities genussscheine psp one nonvoting equity security genussschein per award psp one nonvoting equity security genussschein per award resulting allocations multiplied nonvoting equity security genussschein price december swiss francs give fair value remuneration received employee remuneration equity compensation plans thousands chf roche connect ssar awards psp awards employer ssar ssar psp psp psp psp total contributions number fair value number number number fair value fair value total cec f schwan total remuneration corporate executive committee equity compensation plans million swiss francs million swiss francs attributable dr schwan member corporate executive committee highest total remuneration employee benefits includes tax advisory costs incidental benefits also includes remuneration dr schwan dr hunziker mr burns prof knowles serving chugai board directors special payment dr keller swiss francs years service group transactions former members corporate executive committee pensions tax consulting services totalling million swiss francs paid group four former corporate executive committee members million swiss francs two former members board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table roche finance report roche holding ltd basel notes financial statements shareholdings members board directors nonvoting equity securities shares genussscheine fb humer b g b gehrig hoffmann c p baschera ji bell p brabeckletmathe na na wm burns na na b ljr de vink e w frey da julius f ar levinson na na oeri w ruttenstorfer h teltschik na na b weder di mauro total include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars roche performance share plan see c mr hoffmann entered call options agreement ubs roche nonvoting equity securities period august august mr hoffmann dr oeri held ubs longshort certificates roche bearer shares ro versus roche nonvoting equity securities rog e mr de vink held roche american depositary receipts adrs f close relatives dr julius held roche nonvoting equity securities genussscheine g dr humer held rogtpk trackerplus certificates zrcher kantonalbank underlying roche nonvoting equity secu rities rog corporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan b ayyoubi wm burns na na e hunziker ga keller c jkc knowles na na oday na na j schwiezer na na p soriot total equity compensation awards roche option plan ssars roche performance share plan see b close relatives dr schwan held roche nonvoting equity securities genussscheine c close relatives dr keller held roche nonvoting equity securities genussscheine december chairman board directors mr burns members corporate executive committee held stocksettled stock appreciation rights ssars first issued roche option plan awards issued shown table awards held dr humer current chairman board directors mr burns current member board directors issued previous capacities members corporate executive committee option entitles holder purchase one roche nonvoting equity security genussschein specified strike price terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report included business report part annual report pages roche option plan ssars awards held december year issue total schwan ayyoubi e hunziker ga keller oday p soriot total cec fb humer wm burns total strike price chf expiry date feb feb jan feb feb feb feb dr soriots awards included awards strike price chf expire january december members corporate executive committee shown table mr burns awards held psp awards three psp performance cycles awards held mr burns current member board directors issued previous capacity members corporate executive committee terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report pages business report part annual report award result zero two nonvoting equity securities genussscheine depending upon achievement performance targets discretion board directors end cycle performance targets achieved accordingly participants received none originally targeted nonvoting equity securities genussscheine total target number awards outstanding cycles december shown table roche finance report roche holding ltd basel notes financial statements roche performance share plan awards held december psp psp schwan ayyoubi e hunziker ga keller oday p soriot total cec allocation date feb feb december chairman board directors members corporate executive committee time held total stocksettled stock appreciation rights roche option plan awards outstanding total awards granted roche performance share plan roche holding ltd basel appropriation available earnings roche finance report appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year transfer free reserve total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account roche finance report roche holding ltd basel report statutory auditor financial statements report statutory auditor financial statements report statutory auditor financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying financial statements roche holding ltd comprise income statement balance sheet notes pages year ended december board directors responsibility board directors responsible preparation financial statements accordance requirements swiss law companys articles incorporation responsibility includes designing implementing maintaining internal control system relevant preparation financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion financial statements based audit conducted audit accordance swiss law swiss auditing standards standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures financial statements procedures selected depend auditors judgment including assessment risks material misstatement financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation financial statements order design audit procedures appropriate circumstances purpose expressing opinion effectiveness entitys internal control system audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion financial statements year ended december comply swiss law companys articles incorporation report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag john morris franois rouiller licensed audit expert licensed audit expert auditor charge basel january published cautionary statement regarding forwardlooking f hoffmannla roche ltd tatements basel switzerland annual report contains certain forwardlooking tel statements forwardlooking statements may identi fied words believes expects anticipates fax projects intends seeks estimates future similar expressions discussion among things media office strategy goals plans intentions various factors may group communications cause actual results differ materially future basel switzerland reflected forwardlooking statements contained tel annual report among others pricing product fax initiatives competitors legislative regulatory devel opments economic conditions delay inability obtaining regulatory approvals bringing products market investor relations fluctuations currency exchange rates general basel switzerland financial market conditions uncertainties discovery tel development marketing new products new uses fax existing products including without limitation negative results clinical trials research projects unexpected side effects world wide web pipeline marketed products increased government wwwrochecom pricing pressures interruptions production loss inability obtain adequate protection intellectual property rights litigation loss key executives order publications employees adverse publicity news tel coverage fax email baselwebmasterrochecom statement regarding earnings per share growth profit forecast interpreted mean next annual general meeting roches earnings earnings per share march subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks mentioned enjoy legal protection roche finance report published german english case doubt differences interpretation english version shall prevail german text printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communicationsfhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom